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ABSTRACT OF DISSERTATION 
 
 
MODELING DEMENTIA RISK, CONGNITIVE CHANGE, AND PREDICTIVE 
MODELING IN LOGITUDINAL STUDIES 
              Dementia is increasing recognized as a major problem to public health 
worldwide. Prevention and treatment strategies are in critical need. Nowadays, research 
for dementia usually featured as complex longitudinal studies, which provide extensive 
information and also propose challenge to statistical methodology. The purpose of this 
dissertation research was to apply statistical methodology in the field of dementia to 
strengthen the understanding of dementia from three perspectives:  1) Application of 
statistical methodology to investigate the association between potential risk factors and 
incident dementia. 2) Application of statistical methodology to analyze changes over 
time, or trajectory, in cognitive tests and symptoms. 3) Application of statistical learning 
methods to predict development of dementia in the future.  
         Prevention of Alzheimer’s disease with Vitamin E and Selenium (PREADViSE) 
(7547 subjects included) and Alzheimer’s disease Neuroimaging Initiative (ADNI) (591 
participants included) were used in this dissertation. The first study, “Self-reported sleep 
apnea and dementia risk: Findings from the PREADViSE Alzheimer’s disease prevention 
trial ”, shows that self-reported baseline history of sleep apnea was borderline 
significantly associated with risk of dementia after adjustment for confounding. Stratified 
analysis by APOE ε4 carrier status showed that baseline history of sleep apnea was 
associated with significantly increased risk of dementia in APOE ε4 non-carriers. The 
second study, “comparison of trajectories of episodic memory for over 10 years between 
baseline normal and MCI ADNI subjects,” shows that estimated 30% normal subjects at 
baseline assigned to group 3 and 6 stay stable for over 9 years, and normal subjects at 
baseline assigned to Group 1 (18.18%) and Group 5 (16.67%) were more likely to 
develop into dementia. In contrast to groups identified for normal subjects, all trajectory 
groups for MCI subjects at baseline showed the tendency to decline. The third study, 
“comparison between neural network and logistic regression in PREADViSE trial,” 
demonstrates that neural network has slightly better predictive performance than logistic 
regression, and also it can reveal complex relationships among covariates. In third study, 
the effect of years of education on response variable depends on years of age, status of 
APOE ɛ4 allele and memory change. 
 
KEYWORDS:  longitudinal analysis, dementia, group based trajectory modeling, neural 
network 
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CHAPTER ONE 
 
Introduction 
               Dementia is not a disease but a term that describes a group of symptoms1. It 
indicates a loss of cognitive functioning, such as the loss of the ability to think, 
remember, and reason, as well as behavioral abilities, and it interferes with a person’s 
daily life and activities2.  As the world’s population ages, the prevalence of dementia 
rises.  Prevalence of AD is currently estimated at 5.4 million cases in the United States, 
and the Alzheimer’s Association reports that by 2050 that an estimated 16 million 
Americans will have AD. Researchers estimate that dementia will become the most 
expensive chronic condition associated with aging 3, 4. Given current costs associated 
with the care and treatment of AD, in 2050 the annual cost of AD will reach 1.1 trillion 
dollars5. 
              Many neurological diseases can present as a dementia, but the most common 
cause is Alzheimer’s disease (AD),  which accounts for 60 to 80 percent of dementia 
cases1. Clinically AD usually occurs after age 65. It is characterized clinically by deficits 
in memory and thinking, combined with impaired activities of daily living (ADLs)6.  
Pathologically AD is defined as the presence of beta-amyloid (i.e., neuritic plaques) and 
tau (i.e., neurofibrillary tangles) pathology, which only can be determined at the time of 
autopsy7.  
               In epidemiological studies, researchers often describe a subject’s cognitive 
status as normal, mild cognitive impairment (MCI), or dementia. The term MCI first 
appeared in the Global Deterioration Scale and was described as the earliest clear-cut 
cognitive deficits8.  MCI was often defined as noticeable deficits in memory without 
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significant impact on daily functioning9 . Clinical diagnosis of MCI is based on 
evaluation of medical history, assessment of independent function and daily activities 
with input from family members or friends.  There are no tests or procedures to 
conclusively diagnose MCI. Patients diagnosed with MCI have increased risk to progress 
to dementia 10, but they also can remain at the MCI stage until death, and some of them 
revert to a normal cognitive state11, 12.  
             In longitudinal studies of aging and dementia, healthy subjects without dementia 
and other neurological and/or neuropsychiatric conditions are usually recruited and 
evaluated for cognitive function and functional abilities at baseline and, then followed up 
annually for their cognitive status.  Annual tests of cognition typically include multiple 
cognitive instruments, often collected over multiple decades. Appropriate and powerful 
statistical methods are important to analyze these complex data. In this project, 
application of statistical methodology in the field of dementia will be discussed and then 
performed to strengthen the understanding of dementia from three perspectives:  1) 
Application of statistical methodology to investigate the association between potential 
risk factors and incident dementia. 2) Application of statistical methodology to analyze 
changes over time, or trajectory, in cognitive tests and symptoms. 3) Application of 
statistical learning methods to predict development of dementia in the future.  
Application of statistical methods in association between risk factors and incident 
dementia.        
               Multivariable logistic regression 13-16 and the proportional hazards model 17-22 
are commonly used methods to study risk factors associated with incidence of dementia 
or related binary outcomes based on various research questions.  In the proportional 
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hazards model, time to incident dementia is recorded for individuals and hazard ratios 
and time to event are estimated for groups. Logistic regression is most often used in 
fixed-period follow-up longitudinal studies, which means that subjects are followed up 
for the same amount of  time, and cognitive status is assessed at the end of the study. 
Depending on the research questions and study design, different covariates are often 
incorporated into the statistical model. Some studies have applied multi-state models 23, 24  
to accommodate various research interests regarding risk factors.  
Application of statistical methods in cognitive trajectories or changes over time of 
cognition test or symptom 
              Various statistical methods have been developed and applied to describe change 
in outcomes for cognitive measurements over time and the association between change 
with risk factors, including but not limited to linear mixed effect model (LMM), mixed 
membership trajectory model (MMTM)25, latent change score modeling26, multi-stage 
disease progression model27, Markov processes28, mixed-effects beta regression29, 
boundary inflated beta regression and coarsening model, tract based spatial statistics30, 
and latent profile approach31.   
              LMM is used generally for describing changes in continuous outcomes overtime 
32-34.  One appealing aspect of LMM is that it is very flexible in accommodating any 
degree of imbalance in longitudinal data, which means it does not require the same 
number of observations on each subject nor that the measurements be taken at the same 
occasions.  
             However, LMM depends on several assumptions: (1) outcome of interest is 
continuous; (2) random components of the model are normally distributed; (3) assuming 
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no interaction among the covariates, a one unit change in any predictor is estimated to 
have a constant linear effect on mean level of outcome 35.  There have been some 
arguments about the use of LMM in aging studies 35-37. For example, cognitive tests are 
usually discrete quantitative outcomes with a limited range of possible values and, they 
can suffer from ceiling and/or floor effects. 35, 37  Further, they usually do not change 
linearly over time.   
               Nagin and colleagues developed a longitudinal statistical approach – group 
based trajectory model (GBTM) that can copy the problems noted above. It can 
accommodate the discrete nature and truncated distribution of the outcome. It assumes 
that the sample is composed of a mixture of distinct groups, and that each group of 
individuals follows a similar developmental trajectory in terms of changes at mean level 
of outcome measurements 38-41.  Furthermore, one advantage of GBTM is that it 
qualitatively identifies distinct developmental groups that may not be identifiable by 
using LMM 42, 43. Another advantage is that the model can distinguish real differences 
from chance variation.   GBTM has been applied in prior cognitive studies. For example, 
Xie et al. applied GBTM to identify and characterize 5 trajectories of cognitive change in 
MCI subjects using the Mini-Mental State Examination (MMSE) 44. Their results 
demonstrated heterogeneity of trajectories in MCI patients and that over half of MCI 
subjects follow a stable trajectory over time.  
Application of statistical learning methods to predict development of dementia 
   Early identification of individuals with high risk of dementia is of great 
importance to prevent or delay dementia onset if prevention therapies emerge in the 
future.  Two systematic reviews have covered nearly all parametric research methods 
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used for prediction of dementia risk in the past decades 45, 46. These prediction models 
were mostly developed from logistic regression 47-50 or proportional hazards regression 
analysis 51-56 , and final models were selected based on p values or Bayesian Information 
Criterion.  Performance of these models was assesses for discriminative accuracy, 
sensitivity, specificity, positive predictive value, negative predictive value, and internal 
calibration. C-statistics reported from these models ranged from 0.49 to 0.8948, 57.  Cut-off 
points were only reported in a few studies 47, 55, 58, but none of them had both sensitivity 
and specificity over 80%. These two comprehensive reviews concluded that none of the 
methods are recommended for dementia risk prediction in the population setting due to 
sample selection, model diagnostics, and model validation 45, 46. Only four models 
covered in the two research reviews performed model validation issues 52, 54, 57, 59. From a 
non-parametric model perspective, the classification tree is the most often used method 60, 
61. There are also other statistical learning methods such as random forest62, neural 
network63.  
            The purpose of this study is to assess risk factors and modelling strategies in 
longitudinal studies of aging and cognition. The specific aims of this study are: 
Chapter 2: Investigate the association between sleep apnea and risk of dementia in the 11- 
                 year Prevention of Alzheimer’s Disease by Vitamin E and Selenium  
                 (PREADViSE) trial and whether the association depends on the status of the  
                 unmodifiable genetic risk factor APOE4.  
Chapter 3: Explore potential trajectories in episodic memory scores in normal and MCI  
                  subjects enrolled in the Alzheimer’s disease Neuroimaging Initiative (ADNI)    
                  cohort and assess whether these trajectories differ by cognitive status.  
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Chapter 4: Apply parametric and nonparametric statistical learning methods to create a  
                  prediction rule for predicting the development of dementia in the  
                  PREADViSE study. 
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CHAPTER TWO 
Self-reported sleep apnea and dementia risk: Findings from the PREADViSE 
Alzheimer’s disease prevention trial  
 
Abstract 
             Sleep apnea is a common condition and has a direct impact on cognitive function. 
The impact of sleep apnea, and its interplay with other established risk factors, on the risk 
of incident dementia warrants exploration.To investigate the association between baseline 
sleep apnea and risk of incident dementia in the Prevention of Alzheimer’s Disease with 
Vitamin E and Selenium (PREADViSE) study and explore whether the association 
depends on APOE ɛ4 allele status, randomized controlled dementia prevention trial 
followed by exposure study with over 11 years of follow up was used. Participants were 
assessed at 128 local clinical study sites during the clinical trial phase and later were 
followed by telephone from a centralized location.7,547 male subjects were enrolled in 
PREADViSE, and 4,271 of them consented to participate in the exposure study. 
Participants were interviewed at baseline for sleep apnea. The Memory Impairment Screen 
(MIS) was administered to each participant annually. Subjects who failed to this initial 
screen were tested with secondary cognitive screening tests. Additional measures collected 
include medical history, medication use, and the AD8 dementia screening instrument. The 
effect of self-reported sleep apnea on dementia risk depends on APOE ɛ4 status. When the 
allele was absent, baseline self-reported sleep apnea was associated with a 66% higher risk 
of developing dementia (95% CI 2%-170%), while self-reported sleep apnea conferred no 
additional risk for participants with an ɛ4 allele. Sleep apnea may increase risk of dementia 
in the absence of APOE-ɛ. This may help inform prevention strategies for dementia or AD 
in older men with sleep apnea. 
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Introduction 
            Dementia is a syndrome that affects memory, thinking, behavior and ability to 
perform everyday activities. In 2010, Mimo and colleagues estimated global dementia 
prevalence at 35.6 million people, and this number is expected to double by 2030 and 
more than triple by 2050. Moreover, estimated annual costs of dementia reached $604 
billion (U.S. dollars) in 20103, 4. With rising prevalence, these costs are expected to 
increase by 85% by 2030, which would make dementia the most expensive chronic 
disease associated with aging.  
            Sleep apnea is a common age-associated type of sleep disordered breathing 
(SDB), with clinical symptoms including loud snoring, breathing pauses such as choking 
or gasping during sleep, morning headaches, insomnia, and daytime sleepiness 64-66. 
Sleep apnea and risks associated with it, such as obesity, are becoming an increasingly 
important public health issue for adults 64, 67-71.  The prevalence of sleep apnea varies by 
age and sex and is more common in older adults and men65, 72, 73. It is estimated to be 
present in 20 to 50% of older adults 65. For people aged 50-70 years old, 17% of men and 
9% of women are estimated to have moderate-to-severe SDB74.  
              Sleep apnea is associated with cognitive impairment and dementia in older 
populations75, 76; however, the relationship between pre-existing sleep apnea and incident 
cognitive impairment and dementia remains poorly characterized. Many existing studies 
are limited by cross-sectional study designs, small sample size, or short follow-up time 77, 
78. Three cross-sectional studies in populations aged over 65 years found no association 
between the apnea-hypopnea index and cognitive function 79-81. By contrast, in a 
prospective study of 298 women, Yaffe et al. 82 found that SDB was associated with a 
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71% increased risk of developing mild cognitive impairment (MCI) or dementia over 5 
years after adjusting for age, race, body mass index, education level, smoking status, 
presence of diabetes, and hypertension. A retrospective population-based study also 
showed increased risk of developing dementia for a Taiwanese population aged over 40 
years who attended a national health insurance program 83. Sleep apnea patients had a 
170% increase in dementia risk compared with patients without sleep apnea after 
adjustment for age, sex, hypertension, diabetes, stroke, and hyperlipidemia during the 5-
year follow-up period . Finally, an eight-year study of older adults found only small 
effects of SDB on decline in attention, but not memory, once other medical comorbidities 
were included in their statistical models76. 
              However, these cohort studies were unable to consider the effect of the genetic 
risk factor, APOE84, on risk of dementia. Since APOE is a major unmodifiable risk factor 
for dementia due to Alzheimer’s disease (AD), the most common form of dementia, it is 
important to understand whether sleep apnea or SDB might differentially influence the 
risk of dementia based on the status of APOE genotype.  To our knowledge, only three 
studies have explored this association. O’Hara et al. conducted a small cross-sectional 
study (n=36) and found that SDB was only associated with impairment of verbal memory 
in APOE ɛ4 allele carriers 85, while Osorio and colleagues (n=95) found only a trend 
toward lower CSF Aβ-42 levels in APOE ɛ4 positive normal older adults with SDB 68. A 
second study by Osorio and colleagues based on the Alzheimer’s disease Neuroimaging 
Initiative database (n=2,285) found that SDB was associated with younger age at onset of 
MCI, and this was not affected by APOE ɛ4 carrier status 86. Additional studies are 
needed to investigate this topic.  
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               Using Prevention of Alzheimer’s Disease (AD) by Vitamin E and Selenium 
(PREADViSE) trial data, which comprises 7,547 male subjects who were free from 
dementia at baseline, we sought to investigate two research hypotheses (1) older men 
with self-reported sleep apnea prior to cognitive impairment have an increased risk of 
dementia, and (2) older men with self-reported sleep apnea have different risks for 
dementia based on APOE allele status. 
Methods  
Study population and data sources 
            We conducted a secondary analysis of sleep apnea and incident dementia among 
7,547 subjects enrolled in the PREADViSE trial 87. The PREADViSE trial is an ancillary 
study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (a large prostate 
cancer prevention randomized controlled trial (RCT) 88 and was designed to evaluate the 
effectiveness of antioxidant supplements vitamin E and selenium in preventing incident 
AD and other forms of dementia. PREADViSE investigators were blind to SELECT 
treatment assignment as of this writing, and so the effects of the antioxidant supplements 
will not be considered further here. During the recruiting period from 2002 to 2009, 
PREADViSE enrolled 7,547 non-demented male participants age 62 years and older (age 
60 if African American) from 128 participating SELECT clinical sites in the US, Canada, 
and Puerto Rico. The eligibility criteria for participating in PREADViSE included active 
SELECT enrollment at a participating site, and absence of dementia and other active 
neurologic conditions that affect cognition such as major psychiatric disorder, including 
depression. All 7,547 participants are included in the current study; no further inclusion 
and/or exclusion criteria were applied for this secondary analysis. The study supplements 
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in SELECT were discontinued by its Data Safety Monitoring Committee in 2008 
following a futility analysis 89, and then PREADViSE and SELECT continued as 
observational exposure studies.  The details of this evolution for PREADViSE can be 
found in Kryscio et al. 90. During the RCT phase, SELECT sites used a web-based data 
collection system to submit data directly to the Cancer Research and Biostatistics Group, 
who managed the data for SELECT. SELECT provided monthly snapshots of 
PREADViSE data elements to PREADViSE via a secure file transfer protocol (ftp) site. 
During the observational phase, data were collected at a single site, the University of 
Kentucky. 
                 All participants were asked to continue in the exposure study, and 4,271 of 
7,547 original PREADViSE volunteers consented to participation (Figure 2.1). 
PREADViSE was approved by the University of Kentucky Institutional Review Board 
(IRB) as well as the IRBs at each SELECT study site. Each participant provided written 
informed consent.   
Case Ascertainment 
                The Memory Impairment Screen (MIS)91 was used as the primary screening 
instrument for memory impairment in both the RCT and observational portions of 
PREADViSE. The MIS was given annually. If participants failed the MIS (that is, the 
participant scored 5 or less out of 8 on either the immediate or delayed recall portion of 
the MIS), a second tier screen was administered. An expanded Consortium to Establish a 
Registry in AD battery (CERAD-e)92  was used during the RCT period and the modified 
Telephone Interview for Cognitive Status (TICS-m) 93, was used during the observational 
study. Both the CERAD-e and the TICS-m assess participants’ global cognitive function. 
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Failure on the secondary screen (T score ≤ 35 on CERAD-e battery or total score ≤ 35 on 
TICS-m) would lead to a recommendation for a clinic visit with their local physician. 
Records from the clinic visit were reviewed by 3-5 expert clinicians, including two 
neurologists and at least one neuropsychologist, for a consensus diagnosis. In cases where 
the neurologists disagreed in their diagnoses, the study PI made the final determination. 
Annual screenings were completed in May 2014, and a small number of participants were 
followed for medical records through August 2015. 
            The incident dementia cases were identified through two methods. First, as 
described above, a medical records-based consensus diagnosis was used. Date of 
diagnosis was assigned as the date of the failed screen. Second, because many 
participants were reluctant to obtain medical workups for their memory, additional 
longitudinal measures including the AD8 Dementia Screening Interview 94, self-reported 
medical history, self-reported diagnosis of dementia, use of memory enhancing 
prescription drug, and cognitive scores including the MIS, CERAD-e T Score, NYU 
Paragraph Delayed Recall, and TICS-m were used to identify cases. The diagnostic 
criteria for the second method were AD8 total of ≥ 1 (at any time during follow-up) to 
indicate functional impairment 94 plus one of the following: a self-reported diagnosis of 
dementia, use of a memory enhancing prescription drug (donepezil, rivastigmine, 
galantamine, or memantine), or cognitive score below cutoffs for intact cognition on any 
test (for example: 1.5 SDs below expected performance based on age and education 
normative data95 . The date of diagnosis was assigned to the earliest event.  
Sleep Apnea 
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            All participants were asked during the baseline PREADViSE interview whether 
they had ever been treated for sleep apnea. Responses were recorded as “yes” or “no.” 
APOE genotype 
            APOE genotype was obtained for 7,180 participants (ɛ2/2: 51 (0.71%); ɛ2/3: 879 
(12.24%); ɛ2/4: 190 (2.65%); ɛ3/3: 4,320 (60.17%); ɛ3/4: 1,599(22.17%); ɛ4/4: 
141(1.96%)). The genotypes were converted to a dummy indicator for at least one ɛ4 
allele, where the presence of at least one ɛ4 allele was considered a carrier. SAS 9.4® 
procedure PROC MI was used to impute missing values for the indicator variable 
(367/7547 (5%)) based on family history of dementia. Four imputed data sets were 
generated; participants with two or more positive imputations for APOE ɛ4 were coded as 
APOE ɛ4 positive. APOE ɛ4 positivity is a major risk factor for AD-type dementia 96. 
Other Covariates 
           Other data collected included age at baseline, race, body mass index (BMI), years 
of education, as well as self-reported indicators of cardiovascular disease (i.e., diabetes, 
hypertension, and smoking). These are recognized risk factors for dementia 97.   History 
of significant cognitive or motor impairment due to stroke was a PREADViSE exclusion 
criterion so baseline prevalence of stroke in the cohort is extremely low (0.6%), thus 
stroke was not considered further. 
Statistical analysis 
           Chi-square and t-test statistics were used to examine differences in categorical and 
continuous variables between sleep apnea groups. The log-rank test was used to assess 
differences in crude cumulative risk of dementia between sleep apnea groups. A series of 
Cox proportional hazards regression models with self-reported sleep apnea as the 
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independent variable, survival time to diagnosis of dementia as the dependent variable, 
and the covariates listed above were applied to simple and multivariable survival 
analyses, where follow-up time was defined as the period in years between date of 
PREADViSE study entry and date of dementia diagnosis or, in the absence of dementia, 
date of last assessment.  The multivariable model included main effects for baseline age, 
years of education, body mass index (BMI),  race (black vs. non-black), status of APOE 
(presence of APOE ɛ4 or absence of APOE ɛ4), smoking (yes vs. no), self-reported 
baseline status of diabetes and hypertension (coded present or absent. Covariates were 
fixed at baseline. The proportional hazards assumption was tested by checking the 
interaction between time and each covariate. Interaction terms between history of sleep 
apnea and each covariate in the model were also tested. None of the interactions were 
significant. Given the sufficient sample size in each APOE group (n = 2029 and 5518 in 
APOE ɛ4 positive group and negative group, respectively), we also evaluated the effect 
of sleep apnea on risk of dementia stratified by APOE ɛ4 to evaluate for effect 
modification between sleep apnea and APOE. All data were analyzed by using SAS 9.4® 
(SAS Institute, Inc., Cary, NC), and 0.05 was set as the significance level. 
Results 
            Demographic attributes of participants from PREADViSE are shown in Table 2.1. 
Briefly, 7.3% (552/7547) of the men reported history of sleep apnea at baseline.  The 
absolute difference in baseline age between men with and without sleep apnea was 
significant but not large (Table 2.1).  Men with history of sleep apnea at baseline were 
significantly more likely to be of black race (p = 0.02), smokers (p<0.001), have higher 
BMI (p < 0.001), and were more likely to report hypertension (p<0.001) and diabetes 
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(p<0.001).    No significant differences were observed in educational attainment or 
proportion of APOE ɛ4 carriers. 
           A total of 310 (4.1%) men were diagnosed with dementia (4.0% for men without 
sleep apnea, 5.1% for men with history of sleep apnea, respectively; p = 0.24). The 
cumulative incidence accounting for censoring during follow-up was estimated to be 
9.3% in the non-sleep apnea group and 24.4% in sleep apnea group (Figure 2.2). 
However, this difference was not significant due to the relatively small number of 
dementia cases in the sleep apnea group (p = 0.14 by the log-rank test).  
          Table 2.2 displays hazard ratios for dementia diagnosis from adjusted survival 
analysis.  History of sleep apnea was borderline significant in the adjusted model (HR = 
1.44; 95% CI (0.96 – 2.17, p = 0.08). In this adjusted analysis, men with sleep apnea 
were more likely to develop dementia compared to men without sleep apnea. Black race, 
APOE ɛ4 carrier status, and baseline age were significantly associated with dementia risk. 
Interaction terms between sleep apnea and each covariate in the model were tested, but 
none were significant.  
         Stratified analyses by status of APOE ɛ4 were conducted, and results are shown in 
Table 2.2. For men without an APOE ɛ4 allele, history of sleep apnea conferred a 66% 
(95% CI 2%-170%) higher risk of developing dementia (Figure 2.3a). Sleep apnea had no 
effect when the APOE ɛ4 allele was present (Figure 2.3b).  
Discussion  
         In this study, self-reported baseline history of sleep apnea was borderline 
significantly associated with risk of dementia after adjustment for confounding (p = 
0.08). Stratified analysis by APOE ε4 carrier status showed that baseline history of sleep 
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apnea was associated with significantly increased risk of dementia in non-carriers.  For 
the latter, self-reported sleep apnea was estimated to confer a 66% higher risk to develop 
dementia (p = 0.0423), which is consistent with prior studies.  Age, race, and APOE were 
significantly associated with the risk of dementia in the multivariable Cox model. We did 
not find any significant associations for years of education, smoking, BMI, presence of 
diabetes, or hypertension in either the primary or the stratified analyses with the 
exception of smoking, which significantly increased risk for APOE ε4 carriers. None of 
the two-way interactions between self-reported sleep apnea and other covariates were 
significant, including APOE ε4, which was likely due to a lack of sufficient statistical 
power to detect the interaction despite the difference in the stratified analysis.   
            There are very few prospective studies that have investigated the association 
between sleep apnea and risk of dementia in an older adult male population.  We did not 
find clear evidence that history of sleep apnea, prior to cognitive impairment, was 
associated with dementia in men overall, which is similar to the findings reported in 
Osorio’s recent study86 and several other cross-sectional studies 79-81.  However, our 
results did show that sleep apnea is significantly associated with dementia risk for men 
who were APOE ɛ4 allele non-carriers. This is contradictory to the finding of one small 
cross-sectional study85, which found that the association existed only for APOE ɛ4 allele 
carriers, but similar to Osorio et al.’s study 68, in which CSF amyloid beta 42 and tau 
were not associated with sleep apnea in APOE ɛ4 allele carriers but were associated in 
noncarriers . Such discrepancies are likely the result of differences in exposure and 
outcome assessment, residual confounding, covariates adjusted for, sample size, study 
population, or study design.  
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              Similar to other studies68, 85, our results indicated an interaction effect of sleep 
apnea and APOE ɛ4 on the risk developing dementia. This is particularly important 
considering both the high prevalence of sleep apnea in older populations 65 and the high 
percentage of APOE ɛ4 non-carriers in the population (75%) 98. So far, several prevention 
trials 76, 99 have been completed with null or inconclusive results.  Since the APOE ɛ4 
allele is a well-known and non-modifiable risk factor for AD, the findings of this study 
may help inform prevention strategies for dementia or AD in older men with sleep apnea. 
Osorio and colleagues 86 suggest that treatment with continuous positive airway pressure 
(CPAP) may delay onset of MCI. Thus, diagnosis and treatment of sleep apnea in older 
populations may be helpful in preventing or delaying incident cognitive impairment in 
the aging population with SDB who are APOE ɛ4 non-carriers.  
Possible mechanisms that could explain the association of sleep apnea with risk of 
incident cognitive decline and dementia include direct effects on cerebral oxygenation 
and the selective vulnerability of hippocampal neurons to hypoxia, or perhaps 
augmentation of vascular contributions that have been strongly linked to the development 
of MCI, AD, and other forms of dementia82, 100. Chronic hypoxia has been linked to 
hippocampal injury that may lower the threshold for the development and or spread of 
tau-associated neurodegeneration 101. The development of sleep apnea has also been 
shown to exacerbate cardiovascular risk factors such as hypertension, and to be strongly 
associated with obesity, insulin resistance, hyperlipidemia, and the development of the 
metabolic syndrome91, 102. Thus, there may be many ways that sleep apnea contributes to 
derangements in metabolic pathways that have been strongly associated with increased 
risk of incident MCI or dementia in the aging population. Indeed, the present data 
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demonstrate increased prevalence of hypertension and diabetes in those with sleep apnea, 
although the association with APOE status appeared independent of such conditions in 
the adjusted analysis, suggesting that other mechanistic factors may be important to 
consider. 
              Another possible mechanism for the association of sleep apnea and risk of 
dementia is that sleep may help regulate brain amyloid-β levels 103, 104. A recent study in 
transgenic mice demonstrated that levels of brain amyloid-β increased when both normal 
and AD mouse models were awake and then decreased during sleep 105. This diurnal 
variation in amyloid production could be dramatically altered in persons with sleep apnea 
or other sleep disturbances106.  A small study 107 of community-based older adults was 
able to demonstrate that shorter sleep duration was significantly associated with increased 
amyloid-β levels. There is also some evidence that APOE might play a role in 
degradation of amyloid-β 64. APOE ɛ4 carriers show lower concentration of amyloid-β in 
the cerebrospinal fluid, indicating increased amyloid-β deposition in the brain68. In the 
presence of APOE-ɛ4, any increase in brain amyloid-β associated with sleep apnea may 
be overwhelmed by that due to APOE ɛ4 alone. However, it remains unclear why 
amyloid-β is affected by the sleep cycle or how it depends on the APOE genotype108.  
              This study has some limitations.  Not all participants who failed the memory 
screenings were willing to visit their doctors for a memory work-up, so case 
ascertainment may be less accurate due to lack of medical records. However, application 
of the secondary dementia criteria (positive AD8 screen, self-reported diagnosis, use of 
memory enhancing drug, and poor cognitive scores) demonstrated good agreement in the 
cases where the diagnosis was known (data not shown). Because only a subset of subjects 
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participated in both the RCT as well as the exposure phases of PREADViSE, some cases 
may have been missed among the subjects who did not participate in the exposure study. 
Our data show there were 46.2% participants who had sleep apnea at baseline and did not 
continue to participate in the study, while 50.1% subjects without sleep apnea in the 
baseline cohort did not continue. Therefore, the loss of cases would be estimated to be the 
same for the subjects with and without sleep apnea. We measured sleep apnea with self-
report, similar to Osorio et al. 86. Due to the phrasing of the questionnaire, undiagnosed 
and or untreated sleep apnea subjects may have been missed 109. However, because 
ascertainment of sleep apnea occurred at baseline, it is independent of dementia 
ascertainment. Therefore, if there is misclassification of sleep apnea exposure, it is non-
differential misclassification, and will bias the association toward the null108, that is, to 
lessen the degree of association. Thus, our analysis likely underestimates the effect of 
sleep apnea on dementia risk.  Since the study population is all older men, the findings 
from this study cannot be generalized to older women. However, the current findings 
align quite well with those reported by Yaffe and colleagues who showed an increased 
risk for dementia with SDB in older women82. Strengths for the study include the large 
sample and long follow-up.  We were also able to consider most well established risk 
factors for dementia including demographic, genetic, and medical characteristics, 
including cardiovascular risk factors.  
Conclusion 
               Our study provides evidence that in the absence of APOEɛ4, sleep apnea may 
increase the risk of dementia in older men. This may occur through the disruption of 
brain amyloid-β regulation that occurs during the sleep cycle, or through cerebrovascular 
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damage, although the exact mechanism remains unclear 110. Considering the limited 
number of publications in this area and the inconsistent findings, replication studies with 
objective measures of sleep apnea, long follow-up, and rigorous methods to diagnose 
dementia are needed to support this finding conclusively.  
              From the standpoint of clinical practice, many primary care physicians are 
unaware of their patients’ genetic status and ApoE genotype in particular.  However, with 
adequate screening of SDB symptoms along with other risk factors (e.g., age, ethnicity) 
our findings along with those of O’Hara et al.85 and Yaffe et al. 82 we would advise the 
clinician to work with their patients to address sleep apnea problems as soon as possible 
given the association with future cognitive dysfunction. 
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Table 2.1. General Characteristics of the study sample in PREADViSE 
Characteristic 
All Subjects 
(N=7,547) 
No Sleep 
Apnea 
(n=6995) 
Sleep Apnea 
(n=552) 
 
P value  
Baseline agec, y 67.5±5.3 67.6±5.3 66.6±4.5 < 0.001 
Educationd, y  15.0±2.7 14.9±2.7 15.1±2.6 NSb 
Black race 756 (10.0) 685 (9.8) 71 (12.9) 0.02 
Baseline smokinge 4260 (56.6) 3916 (56.1) 344 (62.4) 0.004 
APOE-ɛ4 (≥1 ɛ4) 2,029 (26.9) 1876 (26.8) 153 (27.7) NSb 
Baseline 
hypertension  
2,998 (39.7) 2703 (38.6) 295 (53.4) <0.001 
Baseline diabetes  858 (11.4) 762 (10.9) 96 (17.4) <0.001 
Baseline BMIaf, 
kg/m2 
28.5±4.4 28.2±4.2 31.6±5.3 <0.001 
Follow-up time, y 5.7±2.8 5.7±2.8 5.5±2.8 NSb 
aBMI: Body Mass Index;  bNS  : Not significant. 
cN = 7546 for age; dN = 7512 for education; eN = 7528 for education ; fN = 7515 for 
education. 
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Table 2.2. Association between History of Sleep Apnea and Risk Dementia based on Adjusted Cox Model and 
Stratified Analysis by APOE ɛ4 Status  
 
 
 
 
 
 
 
 
Table3. Subgroup analysis by status of APOE ɛ4 for time to diagnosis of dementia 
  
 
 
Adjusted HR*  & (95% CI) 
 
Stratified Analysis 
  APOE ɛ4 carriers 
(N = 2029) 
 
 
APOE ɛ4 non-carriers 
(N = 5518) 
 
 Adjusted HRa  & 
 (95% CI) 
 Adjusted HRa  & 
 (95% CI) 
Sleep apnea 1.44 (0.96-2.17)  1.13 (0.54-2.37)  1.66 (1.02-2.70) 
Baseline age, 1 year 1.11 (1.09-1.13)  1.14 (1.10-1.17)  1.09 (1.07-1.12) 
Education, 1 year 0.98(0.94-1.02)  1.01 (0.94-1.08)  0.95 (0.91-1.01) 
Black race 1.73 (1.19-2.52)  1.71 (0.97-3.03)  1.72 (1.05-2.82) 
Baseline smoking 1.20 (0.95-1.51)  1.55 (1.06-2.26)  1.03 (0.77-1.38) 
APOE ɛ4 presence 
presence 
1.99 (1.58-2.50)               --               -- 
Baseline hypertension 0.92 (0.73-1.17)  0.83 (0.56-1.21)  0.98 (0.72-1.33) 
Baseline diabetes 1.10 (0.78-1.57)  0.83 (0.43-1.58)  1.29 (0.85-1.97) 
BMI 0.99 (0.97-1.02)  1.00 (0.95-1.04)  0.99 (0.96-1.03) 
 aAll variables listed in the table were included in the adjusted models. 
Note: Results presented are mean±SD or N (%). All PREADViSE participants are male.  
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Figure 2.1. Participant flow diagram for PREADViSE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*PREADViSE was an ancillary study to SELECT; enrollment was from May 2002 
through November 2009 (N=7,547). PREADViSE participants were invited to participate 
in centralized follow-up (PREADViSE CFU) following the closure of SELECT due to a 
futility analysis. Some SELECT sites decided not to offer their participants the 
opportunity to participate in CFU; these participants are listed above as being ineligible. 
PREADViSE CFU continued to follow participants from August 2010 – August 2015. 
 
 
 
 
 
 
 
 
7,547 participants 
consented to 
PREADViSE 
552 deceased 
654 withdrawn 
1,046 refused PREADViSE CFU* 
1,024 ineligible for PREADViSE CFU* 
4,271 participants 
consented to 
PREADViSE CFU* 
207 deceased 
278 withdrawn 
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 Figure 2.2.  Probability of dementia by history of sleep apnea (SDB) at baseline. Solid 
line indicates sleep apnea, dashed line indicates no sleep apnea.  Time axis ends at 10 
years for consistency among figures. 
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Figure 2.3.  Probability of dementia at baseline by history of sleep apnea (SDB) status 
after adjusting other covariates in APOE ɛ4 non-carriers (a) and carriers (b). These 
hypothetical participants are white, age 68 at baseline, smoke, have 15 years of education 
and baseline BMI 28.5 kg/m2, and comorbidities including presence of hypertension and 
diabetes. Solid line indicates sleep apnea, dashed line indicates no sleep apnea. Time axis 
ends at 10 years for consistency among figures.  
 
(a) 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
CHAPTER THREE 
Evaluating trajectories of episodic memory in normal cognition and mild cognitive 
impairment: results from ADNI 
 
 
ABSTRACT 
               Memory assessment is one of the key components for diagnosis of mild 
cognitive impairment (MCI) and dementia. Identifying individuals who are likely to 
follow particular memory trajectories overtime could inform prevention efforts and 
enhance clinical trial recruitment. To identify the developmental trajectories in memory 
testing and risk factors associated with these trajectories among cognitively normal and 
MCI subjects at baseline, 591 Alzheimer’s Disease (AD) Neuroimaging Initiative 
(ADNI) subjects were administered the Rey Auditory Verbal Learning test (RAVLT) for 
up to 9 years.  Group based trajectory modeling was applied separately to identify distinct 
trajectories in baseline normal and MCI subjects. Six trajectories were identified based on 
the baseline score of the 30-mintute RAVLT delayed recall score for baseline normal 
subjects. They can be summarized as three major types: stable (group 3 and 6, ~32%), 
curvilinear decline (group 4 and 5, ~ 28%), and linear decline (groups 1 and 2: ~ 42% of 
subjects). In contrast to baseline normal subjects, the 5 trajectories identified for MCI all 
tended to decline. Age, gender and education were significantly associated with 
trajectories for both baseline normal and MCI subjects, while APOE ɛ4 allele was only 
significantly associated with trajectories among baseline MCI subjects. The above results 
provide evidence for the heterogeneity of developmental memory trajectories. 
Furthermore, our study also supports prior studies suggesting heterogeneous outcomes 
for the progression of MCI progressing, even among a highly selected sample of patients.  
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INTRODUCTION 
             From a clinical and research perspective, an individual’s cognition may be 
categorized as unimpaired (normal cognition), mildly impaired (mild cognitive 
impairment or MCI), or moderately to severely impaired (dementia). Over time, normal 
cognition can stay stable or decline to MCI or dementia.  Similarly, MCI can stay stable, 
progress to dementia, or revert to normal11.  Therefore, examining potential trajectories 
within certain populations and identifying individuals who are likely to follow particular 
cognitive trajectories could inform prevention efforts and enhance clinical trial 
recruitment by identifying subjects at high risk of cognitive decline.  
              Memory assessment in neuropsychological testing is one of key elements in the 
diagnosis of MCI and dementia 111. One of most commonly used tests for verbal memory 
assessment is the Rey Auditory Verbal Learning Test (RAVLT)112,  which is designed to 
evaluate episodic memory in persons age 16 and older 113. The RAVLT provides 
measures of immediate memory span, learning, and delayed recall, so severity of memory 
dysfunction and changes over time can be evaluated. For instance, MCI patients show 
poorer learning than ‘recovered’ MCI and healthy control groups 114. The RAVLT is 
easily administered, so clinicians often prefer it to other list learning tests, especially 
under conditions of limited assessment time 115. RAVLT performance is influenced by 
subjects’ demographic characteristics, including age, education, and gender 116, 117.  
                  Poor performance on the test is considered a prognostic marker for MCI and 
dementia 118-120. Zhao et al.’s 121 study shows that RAVLT performs better than the 
Complex Figure Test (CFT) for predicting progression from MCI to AD,  and data from 
the Canadian Study of Health and Aging demonstrate that RAVLT short delayed recall 
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may be used to predict incident dementia 50. In the Gothenburg MCI study 122, 
neuropsychological tests including RAVLT, along with hippocampal volume and 
cerebrospinal fluid markers, were used to predict progression from MCI to dementia 
within a follow-up time of two years. They found that a combination of all markers was 
the most successful to predict dementia, but the RAVLT was the best individual predictor 
for dementia. RAVLT was also used to distinguish AD from other types of dementia 123, 
124.  
               In this analysis, we explored trajectories of episodic memory using Group 
Based Trajectory Modeling (GBTM) and longitudinal RAVLT measures for two groups 
of research participants: Alzheimer’s disease Neuroimaging Initiative Phase 1 (ADNI1) 
subjects with normal cognition at baseline and ADNI1 subjects with MCI at baseline. 
Key questions focus on what are the trajectories for baseline normal and MCI subjects 
and whether trajectories differ between baseline normal and MCI subjects over time. In 
addition, we investigate whether trajectories in cognitively normal subjects and subjects 
with MCI at baseline predict incident dementia using predicted trajectory membership as 
a risk factor.  
METHODS    
Sample population and data sources 
              Data were obtained and downloaded from the ADNI database 
(http://adni.loni.usc.edu/) on June 3, 2015. The primary goal of the project is to obtain 
and assess clinical, imaging, genetic and biospecimen biomarkers related to the 
development and progression of AD and develop treatments that may slow the 
progression of AD 125.  
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               Because our interest is focused on longitudinal change, our analysis was limited 
to ADNI1 participants since they have the longest follow-up. During ADNI1, which 
began recruiting participants in 2004, 400 MCI subjects, 200 subjects with early AD, and 
200 control subjects, all aged 55- 90 years, were targeted for recruitment at 50 study sites 
across North America (actual enrollment: 397 MCI subjects and 229 normal control 
subjects, respectively). They were followed-up at 6-month intervals (from study baseline 
to 9 years).  All ADNI research activities were approved by Institutional Review Boards 
(IRB) at the participating study sites, and all participants provided written informed 
consent. The University of Kentucky IRB declared this secondary analysis of ADNI data 
exempt since the ADNI data are de-identified. 
Inclusion and exclusion criteria  
                All analyses for the current study were based on MCI and control subjects who 
enrolled into ADNI1 (actual enrollment: 397 MCI subjects and 229 normal control 
subjects, respectively) and had any follow-up visits in ADNI 1, ADNIGO, or ADNI2.  
Fourteen subjects (1 American Indian, 12 Asian, and 1 more than one race) were 
excluded from the analysis due to small number in their race categories. Twenty-one 
subjects with only one visit were also removed from the analyses, which left 591 total 
subjects for analysis: 219 normal subjects and 372 MCI subjects.  
Rey Auditory Verbal Learning Test (RAVLT) 
                   The RAVLT is a list-learning task that measures auditory verbal memory 126.  
The RAVLT is conducted using two 15-item lists of unrelated words (List A and List B) 
that are read to the participant in a series of trials. To begin, List A is read to the 
participant, and the participant is asked to repeat as many of the 15 words as they can, 
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and the number of correct words is recorded. This procedure is repeated in another 4 
trials, which results in 5 learning trial scores. Then the examiner reads the second list of 
15 words (List B) to the participant, and the participant is asked to recall as many of 
words in List B as possible. Next, the participant is again asked to recall the words in List 
A, and the number of words (immediate recall score) correctly recalled is recorded. The 
participant is then given different tasks to do for 30 minutes. After 30 minutes, the 
participant is asked again to recall as many words as they can from List A, and the 
number of correct words (30-minute delayed recall) is recorded. Last, the participant is 
asked to recognize the words in List A when presented a sheet containing the 15 List A 
words plus 15 distractor words, and examiner records the number of successes 
(recognition score).  
             In the current study, the 30-mintute delayed recall score, which ranges from 0 to 
15 127, is the outcome of interest.   
APOE genotype 
             APOE genotype which is significantly associated with cognitive trajectory 128 
was obtained for all 591 participants (ɛ2/2: 2 (0.34%); ɛ2/3: 46 (7.78%); ɛ2/4: 13 
(2.20%); ɛ3/3: 281 (47.55%); ɛ3/4: 199 (33.67%); ɛ4/4: 50(8.46%)). The genotypes were 
converted to an indicator for a carrier of at least one ɛ4 allele.  
Covariates 
                 Covariates of interest included age at baseline, race, gender, smoking 
information, body mass index (BMI) at baseline, years of education, as well as self-
reported indicators of cardiovascular disease risk (i.e., diabetes, and hypertension) and 
sleep apnea. Age at baseline was calculated based on the participant’s birthdate and exam 
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date. Race was coded as a dummy variable: 0 (as black) and 1 (as White). Similarly, 
smoking was coded as 0(non-smoker) and 1(current smoker). Since ADNI collects 
medical history as single-field text strings (variable “mhdesc”), the self-reported status of 
hypertension, diabetes, and sleep apnea was extracted by searching for keywords. For 
example, the subjects with sleep apnea were identified by first converting all “mhdesc” 
text string values to uppercase, and then a search for the text string ‘SLEEP’ was used to 
find subjects who reported sleep problems. Then each identified case was checked 
individually to confirm sleep apnea. A similar procedure was conducted for status of 
hypertension (keywords: “HYPERTENSION”, “HIGH BLOOD PRESSURE”) and 
diabetes (keyword: DIABETES). Misspelled conditions in the raw data were identified 
when each individual value was checked.  These three variables were coded as dummy 
variables (0 = not reported and 1= reported). 
Statistical Analysis 
             Baseline differences between normal and MCI subjects were assessed with Chi-
square and t test statistics except that number of examinations and months of follow-up 
were conducted through Mann-Whitney Wilcoxon test. GBTM 129, 130 was applied to 
identify different longitudinal trajectories and estimate mean level of RAVLT 30-minute 
delayed recall scores for normal and MCI subjects separately. Trajectory analysis 
assumes that the study population is a mixture of several latent subgroups. According to 
this hypothesis, in each latent subgroup the 30-minute delayed recall score follows a 
distinct trajectory over time. To implement GBTM, the outcome was modeled first as a 
function of time and latent groups were identified. Next, the proportion of the population 
that follows each latent trajectory was estimated. Individuals were assigned to specific 
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latent groups based on the largest posterior probability of group membership for each 
individual. Finally, the analyses examined how the probability of trajectory group 
membership varied with covariates versus an arbitrary reference trajectory group. In the 
present study, covariates of interest included age, race, gender, APOE ε4 carrier status, 
education, hypertension, diabetes, sleep apnea, BMI, and smoking status.  
                   To find the best fitting model to predict trajectory group membership, various 
models including all 10 covariates were fitted for 2 to 6 trajectories (inclusive) 44  and all 
combinations of orders (quadratic was the highest order) of each group. Bayesian 
Information Criterion (BIC) was applied to select the best number of groups and orders 
43. Then log-likelihood ratio tests were applied to reduce the number of covariates in the 
model. Censored normal distribution (CNORM) was applied to normal subjects, while 
Zero Inflated Poisson (ZIP) for modeling excess zero counts were used for MCI subjects 
based on histograms of the outcome in each study population (data not shown). To fit 
CNORM in the normal sample, the 30-minute delayed recall score was standardized by 
subtracting the baseline sample mean (7.5) and dividing by the sample standard deviation 
(3).  The ZIP model assumes that some zeros occur in the Poisson process, and others are 
from a separate always zero generating process. There are two processes in the ZIP 
model – one is to determine if the individual is eligible for a non-zero response, the other 
estimates the mean of a Poisson distribution from which  a count of response  can be 
generated for eligible individuals. Furthermore, the eligibility of a non-zero response for 
an individual may vary with time. These two processes are fit simultaneously with two 
separate regression models: logistic regression to model the probability of being eligible 
for a nonzero count, and Poisson regression to model the size of the count. For simplicity, 
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we assumed that the probability logit for being eligible for a zero count in the ZIP model 
was common to all trajectory groups and constant over time.  
                      The final fitted model provides descriptive information on the estimated 
groups, including (1) posterior probabilities of an individual belonging to one of the 
identified groups, (2) the proportion of each study group following the same latent 
trajectory, (3) regression parameters to define the shape of the trajectories over time 
(intercept only, linear, and quadratic in the present study), (4) risk and protective factors 
associated with membership in a trajectory group. 
                  All data were analyzed by using PC-SAS 9.4® (SAS Institute, Inc., Cary, 
NC), and 0.05 was set as the significance level. Group trajectory analyses were carried 
out using the SAS procedure PROC TRAJ 129, 130.  
Results  
                       Table 3.1 presents the characteristics of participants overall and 
participants by cognitive status at baseline. Normal subjects were followed up longer than 
MCI subjects (p < 0.001). Also, normal subjects were older (p = 0.039), more highly 
educated (p = 0.049), more likely to be female (p = 0.007), and had higher BMI than MCI 
subjects (p = 0.037). Normal subjects comprised fewer APOE-ɛ4 allele carriers and 
subjects with sleep apnea than MCI subjects. Over 91% of subjects had > 3 examinations. 
There were 2476 total observations from MCI subjects and 1541 observations from 
normal subjects.  
Potential groups identified by GBTM 
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                  GBTM identified distinct latent groups in the normal and MCI study samples. 
For normal subjects, 6 latent groups were identified (Figure 3.1) while for MCI subjects 5 
groups were identified  (Figure 3.2) based on the best BIC values among the candidate 
trajectory models. Table 3.2 shows descriptions of the trajectories for normal MCI 
subjects, including the shape of each group trajectory and the number of probable 
members. Trajectories were numbered in order of the estimated mean of 30-minute 
delayed recall at baseline.  
                Baseline normal subjects showed three types of trajectories over time: stable 
(groups 3 and 6: ~30% of subjects), curvilinear decline (groups 4 and 5: ~28% of 
subjects), and linear decline (groups 1 and 2: ~ 42% of subjects). Table 3.3 shows 
characteristics for the trajectory groups. For normal subjects, Group 6 is youngest, and 
has the most male subjects and most years of education.  Subjects in group 3 are oldest, 
group 5 has the most year of education and most male subjects in MCI group. As shown 
in Figure 3.1, group 6 (n = 22) and group 3 (n = 44) remained relatively stable over 9 
years of follow-up but had different intercepts. Group 5 (n = 30) showed slow curvilinear 
decline during the first 4 years of follow-up and faster decline after 4 years, and Group 4 
(n = 31) revealed mild curvilinear decline. Table 3.3 shows the observed frequency of 
cognitive status at end of follow-up by assigned group memberships. The majority of 
subjects assigned to Groups 3 and 6 remained cognitively normal at the end of follow-up, 
and only 5 subjects in Group 3 progressed to MCI status. No subjects in Groups 3 or 6 
progressed to dementia by the end of follow-up. Groups with members most likely to 
develop dementia by end of follow-up were Groups 1 (18%) and 5 (17%). Details of 
parameter estimates for each trajectory are included in Table 3.2.  
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                   In contrast to groups identified for normal subjects, all potential trajectory 
groups for MCI subjects showed the tendency to decline, with the exception of group 2, 
which starts near and  stays around “0” (floor effect). Subjects in Group 1(n = 143) and 
Group 2 (n = 66) were most likely to develop dementia by end of follow-up, with over 
70% of each group progressing (Table 3.3). Subjects in Group 3 (n = 66) had a slightly 
better chance  to remain in MCI (52%) than progressing  to dementia (48%), while the 
majority of subjects in Groups 4 (70%) and 5 (65%) remained MCI. Interestingly, 11% 
subjects in group 4 (n = 73), and 22% subjects in Group 5 (n = 23) had reverted to normal 
cognition by the end of follow-up. None of the MCI subjects in Groups 1 – 3 reverted 
back to normal status by the end of follow-up.  
               For all 6 normal groups and all 5 MCI groups (Table 3.2), the averages of the 
posterior membership  probabilities were greater than 0.7, which indicates that the 
models are acceptable based on the Nagin’s ‘rule of thumb’ on minimum average 
posterior probability 131. 
Risk factors associated with probability of trajectory group membership 
                Table 3.4 presents the parameter estimates for the risk factors associated with 
trajectory group membership. The comparison group is Group 4 for both normal and MCI 
subjects, which was arbitrarily selected. Based on BIC and log-likelihood ratio test, age, 
BMI, and education were retained in both the 6-group model for normal subjects and 5-
group MCI model (Table 3.4) , while gender only stayed in model for normal subjects, 
and  APOE ɛ4 was only in the model for MCI subjects (Table 3.4). Demographic 
variables associated with group memberships among baseline normal subjects (vs. Group 
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4) included female gender (p = 0.02 for Group 6), older age (p = 0.03 for Group 2) and 
higher education (p = 0.02 for Group 2, and p = 0.01 for Group 3).  For example, in 
group 2 for baseline normal subjects, it was estimated that each additional year of 
education increase reduces probability  of belonging to Group 2 vs. the probability of 
belonging to Group 4 by 22% (probability ratio[PR] = 0.78) ,which means that subjects 
with higher education were more likely to  be classified into Group 4 than Group 2. 
Similar effects were observed for Group 1 vs. Group 4.  
                For baseline MCI subjects, APOE ɛ4 allele was a risk factor for being in 
Groups 1 and 2 (p = 0.002 and p < 0.001, respectively) which means that APOE ɛ4 allele 
carriers would be more likely to be Group 1 or Group 2 than Group 4 ( see Table 3.3). 
The APOE ɛ4 allele carriers increased the PR  of belonging to Group 1 vs. belonging to 
Group 4 by 85%, and the probability of belonging to group 2 vs. belonging to group 4 by 
388%, holding other covariates constant in the model. Based on Table 3.4, age is not 
significant but kept in the model, which may suggest that age cannot distinguish the rest 
groups from reference Group 4, but it may distinguish Group 3 from Group 2 (data not 
shown). BMI was significant in Group 1 (p = 0.02) and 2(p <0.001) which suggests 
higher BMI will move subjects out of Group 1 or Group 2 into Group 4.  
Discussion  
              In the current study, we estimated the trajectories of RAVLT 30-minute delayed 
recall scores over 9 years of follow-up in baseline ADNI normal and MCI subjects. 
Normal subjects showed three patterns: stable, linear decline, and curvilinear decline, 
while trajectories for MCI subjects were more heterogeneous.  For normal subjects, 
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subjects assigned to stable trajectory groups (Groups 3 and 6) were more likely remain 
cognitively intact. Notably, none of the subjects in Groups 3 or 6 converted to dementia 
during the 9-year study period. Normal subjects in Group 1 (which had the lowest 
estimated baseline mean score) and Group 5 (which showed faster decline after 4 years 
follow-up) were more likely to develop dementia compared to other groups of normal 
subjects. Different from baseline normal subjects, MCI subjects in Groups 1 and 2 (which 
account for ~56% of all baseline MCI cases) were more likely to progress to dementia, 
while Group 3 subjects had a close chance to stay at the MCI stage (52%) or progress to 
dementia (48%). Subjects in Groups 4 and 5 were more likely to stay in the MCI stage, 
but they also show the most potential to revert back to clinically cognitive normal which 
provided evidence for supporting disparate outcomes for MCI subjects.  
                A finding of this study was that baseline normal subjects had two trajectory 
groups that, on average, exhibited stable memory; none of them progressed to dementia 
by end of follow-up. Also, our study found that a small percentage of baseline normal 
subjects demonstrated stable or improving memory trajectories in mean level, and then 
suffer fast decline; these subjects had higher probability to progress to MCI/dementia.   
                   In comparison with three trajectory groups in AIBL study (Australian 
Imaging, Biomarkers and Lifestyle) 132 and four groups in WHICAP (Washington 
Heights Inwood Columbia Aging Project)128, we identified 6 trajectory groups for 
baseline normal subjects.  Similar to the above two studies, we identified stable and 
decline groups for baseline normal subjects and two curvilinear groups as well. Group 5 
was stable for the beginning 4 years, then showed fast decline in the following year 
which suggested that those subjects were initially cognitively stable or even better but 
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experience an event associated with cognitive impairment and dementia, such as 
restricted mobility 133-135. Comparing to 65.5% and 50% subjects assigned into stable 
groups for AIBL study and WHICAP, respectively, we had proportionally less subjects 
assigned to the stable groups ( Group3 and Group 6; about 30%). This inconsistency may 
be due to the larger number of groups identified in our study, the longer follow-up time in 
our analyses (9 years vs. 4.5 years in AIBL study and 6 years in WHICAP), as well as 
different inclusion and exclusion criteria within each study.  
                To our knowledge, this is one of a few studies to explored memory trajectories 
in MCI subjects. Although most of the potential trajectory groups show a tendency to 
decline except Group 2 stay around 0 over time, 11% and 22% MCI subjects in Groups 4 
and 5, respectively, reverted back to normal cognitive status (determined by clinical 
diagnosis), and 19% and 13% progressed to dementia, respectively, which supports the 
evidence for disparate outcomes often reported in MCI subjects 43, 136, 137.  The 
trajectories in Groups 1 and 2 began with lower scores (Table 3.1s in the appendix shows 
mean of RAVLT 30-minute delayed recall around 0), and the majority (73% in Group 1 
and 71% in Group 2) progressed to dementia, which may indicate the subjects in these 
two groups were already at a late stage of MCI at enrollment. Based on our results, the 
rate of incident dementia from MCI may be correlated with the baseline mean of RAVLT 
30-minute delayed recall. The higher the baseline mean value was, the lower the 
conversion rate.  Overall, the 9-year cumulative incidence of dementia from MCI was 
53% (roughly 6% per year), which is comparable to the 5-year cumulative incidence of 
dementia from MCI reported in specialist centers (39%, or roughly 8% per year)138.  
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                  Different demographic variables were associated with trajectory membership 
for normal and MCI subjects. For baseline normal subjects, older age and less education 
were significantly associated with being in the “linear decline” group (Group 2),  and 
subjects with less education is more likely to be in Group 3 than being Group 4. Being 
female was associated with a stable trajectory (Group 6), which was confirmed in Table 
3.3 (female 77%), but was inconsistent with Lin’s study 139. In baseline MCI subjects, 
genetic risk factor APOE-ɛ4 allele and/or  lower BMI was associated with lower memory 
scores (Group 1 and Group 2).  
Strengths and limitations 
                 The strengths of this study included relatively large baseline sample size (219 
for normal and 372 for MCI), frequent clinical assessments, standardized diagnostic 
criteria for cognitive status, and standardized data collection procedure across multiple 
study sites. This allowed more comprehensive investigation of memory trajectories and 
their relationship with risk or protective factors using long follow-up and multiple visits 
(up to 12 visits for over 9 years).   
                 One potential limitation for the study sample is that the subjects in ADNI may 
not be representative of the general population of older adults in the United States. We 
focused only on participants from ADNI1 in order to obtain participants with longer 
follow-up, so we excluded the early MCI subjects recruited in ADNIGO and late MCI 
subjects enrolled in ADNI2 due insufficient follow-up. The diagnosis of MCI was made 
without further specifying the subtype of MCI (i.e., amnestic, nonamnestic, single 
domain, multiple domain), thus a more homogeneous set of trajectories may exist within 
subtypes of MCI subjects. In the future studies, we aim to validate these trajectories using 
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MRI or biomarker data, and identify unique trajectories for subsets of MCI subjects (i.e., 
early mild cognitive impairment (EMCI), early mild cognitive impairment (LMCI)). 
                  Another limitation is the uncertainty of group membership. Even though the 
average posterior probability is high, the parameter estimates in the model are biased. 
Also in general, although demographics and baseline scores may provide some guidance, 
patients cannot be assigned with accuracy to any trajectory at initial visit but only after 
the subject has been followed for several assessments.  
CONCLUSION  
                    Group based trajectory modeling can be used to identify distinct latent 
subgroups of older subjects based on memory trajectory. The relationship between 
trajectory group and cognitive status at the end of study period confirmed that memory 
trajectory is an excellent indicator of dementia. If trajectory group membership can be 
identified reliably during early follow-up, such work will allow clinicians to monitor or 
predict progression of individual patient’s cognition.  
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Table 3.1. Subject characteristics for ADNI1 participants and by cognitive status 
Characteristic 
All Subjects 
(N=591) 
Normal 
(n=219) 
MCI 
(n=372) 
P valued 
Number of examinations(range 2 – 12)     
        1/2/3/4+ 0/27/25/539 0/7/4/208 0/20/21/331  
        Mean ±SD 7±3 8±3 7±3  
        Median 7 9 6 <0.001 
Months of follow-up (range 6 – 108)     
        Mean ±SD 54±31 64±30 49±29  
        Median 48 72 36 <0.001 
Baseline ageb, y 75.2±6.6 75.9±5.1 74.8±7.3 0.039 
Educationb, y  15.8±2.9 16.1±2.8 15.6±3.0 0.049 
White racec 562 (95.1) 204 (93.2) 358 (96.2) 0.094 
Male genderc 352 (59.6) 115 (52.5) 237 (63.7) 0.007 
Baseline smokingc 235 (39.8) 84 (38.4) 151 (40.6) 0.592 
APOE-ɛ4 (≥1 ɛ4 allele) c 262 (44.3) 58 (26.5) 204 (54.8) <0.001 
Baseline sleep apneac 60 (10.2) 14 (6.4) 46 (12.4) 0.020 
Baseline hypertensionc  278 (47.1) 105 (48.0) 173 (46.6) 0.757 
Baseline diabetesc  49 (8.3) 19 (8.7) 30 (8.1) 0.802 
Baseline BMIab, kg/m2 26.4±4.1 26.8±4.3 26.1±4.0 0.037 
aBMI: Body Mass Index ; b mean ± standard deviation; ccount (%). d P values for continuous variables from 
t test statistics  and P values for categorical variables from Chi-square test except that p values  
 for number of examinations and months of follow-up were from Mann-Whitney-Wilcoxon. 
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Table 3.2. Description of identified groups from the trajectory modeling 
Identified group  
membership  
%a nb 
 
Trajectory 
polynomialc 
P value for 
trajectory polynomiald 
Parameter estimates of trajectory groupe 
Posterior probabilityf 
  Mean± SD(min) Intercept(SE) Slope(SE) Quadratic(SE) 
Baseline normal 
1 15.1 33 Linear <0.001 -1.48(0.05) -0.11(0.01) - 94.9±11.6(62) 
2 26.6 58 Linear <0.001 -0.56(0.04) -0.11(0.01) -       95.9±9.7(51) 
3 20.2 44 Quadratic 0.51 -0.0001(0.01) 0.001(0.03) 0.003(0.004) 92.6±13.2(56) 
4 14.2 31 Quadratic <0.001 0.67(0.07) 0.27(0.04) -0.03(0.006) 91.7±14.7(54) 
5 13.8 30 Quadratic <0.001 0.47(0.07) 0.11(0.06) -0.05(0.006) 92.8±12.3(52) 
6 10.1 22 Linear <0.001 1.74(0.06) 0.11(0.02)  97.0±10.3(54) 
Baseline MCI 
1 38.5 143 Linear <0.001 0.25(0.16) -0.70(0.08) - 95.5±9.3(53) 
2 17.8 66 Quadratic 0.012 -9.94(2.63) 4.20(1.47) -0.53(0.21) 83.5±9.5(61) 
3 17.8 66 Linear <0.001 1.18(0.08) -0.14(0.03) - 87.3±15.2(38) 
4 19.7 73 Linear 0.0159 1.73(0.05) -0.02(0.01) - 90.5±13.5(51) 
5 6.2 23 Linear 0.6103 2.34(0.04) -0.01(0.01) - 95.8±10.6(52) 
Note: %a = percent of subjects were assigned in the trajectory group based on the greatest posterior probability for the subject; b= number of 
subjects in the trajectory group; c = highest term of polynomial for the trajectory group;  d  = p value for highest term of polynomial for the 
trajectory group;  e  = parameter estimates in each trajectory group( intercept, slope, quadratic), SE = standard error of each parameter estimate; 
f  = average  and standard deviation of greatest posterior probability for all subjects assigned in the trajectory group, min = minimum posterior 
probability in the trajectory group.   
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Table 3.3. Characteristics of the subjects in each trajectory group 
Potent
ial 
Trajec
tory 
group 
n Agea Educationa Femaleb APOE-ɛ4b BMIa 
Follow-up 
timea 
(Months) 
 
Baseline 
RAVLTa 
Cognitive Status at end of follow-upc 
 Normal MCI Dementia 
Baseline normal Subject 
1 33 76.4±5.4 16.2±2.6 42.4 30.3 25.1±3.6 52.4±30.4 3.3±1.8 19(57.6) 8(24.2) 6(18.2) 
2 58 77.1±5.2 15.6±2.9 34.5 25.9 27.4±4.0 56.9±31.4 6.2±2.7 39(67.2) 14(24.1) 5(8.6) 
3 44 76.0±4.9 15.3±2.9 56.8 22.7 26.7±4.1 69.3±28.7 6.9±3.0 39(88.6) 5(1.4) 0(0.0) 
4 31 75.0±5.7 16.9±2.8 41.9 19.4 27.5±3.8 70.8±28.1 9.4±3.1 28(90.3) 2(6.5) 1(3.2) 
5 30 75.6±4.8 16.1±3.3 50.0 33.3 26.1±5.6 73.2±27.9 9.1±2.2 20(66.7) 5(16.7) 5(16.7) 
6 22 74.4±3.5 17.2±1.8 77.3 31.8 28.0±5.0 68.2±29.3 12.9±2.3 22(100.0) 0(0.0) 0(0.0) 
Baseline MCI subject 
1 143 73.9±7.3 15.3±3.2 42.0 61.5 25.5±3.7 44.2±25.9 1.5±1.6 0(0.0) 39(27.3) 104(72.7) 
2 66 75.1±7.1 15.9±2.5 34.9 78.8 25.2±3.5 38.9±27.4 0±0 0(0.0) 19(28.8) 47(71.2) 
3 66 77.5±5.9 14.8±3.1 19.7 42.4 27.4±4.1 55.4±29.1 3.3±1.9 0(0.0) 34(51.5) 32(48.5) 
4 73 73.9±8.3 16.0±2.7 34.3 37.0 26.9±4.3 54.3±33.0 5.6±3.0 8(11.0) 51(69.9) 14(19.2) 
5 23 74.0±7.5 17.2±2.3 56.5 34.8 26.2±4.6 68.6±30.1 10.1±3.2 5(21.7) 15(65.2) 3(13.0) 
Note:  RAVLT = Rey Auditory Verbal Learning Testing; a =mean ± standard deviation; b=percentage; c= count (%). 
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Table 3.4. parameter  estimate for risk factors associated  with each 
trajectory group   
Trajectory 
 group  
Parameter Estimate (SE)a p-value 
Normal Subjects    
1 Intercept   0.93 (2.95) 0.75 
       Age        0.06 (0.04) 0.16 
       BMI       -0.12 (0.06) 0.06 
       Gender   -0.41 (0.60) 0.49 
       Education  -0.10 (0.11) 0.40 
2 Intercept   -1.31 (3.60) 0.72 
       Age        0.09 (0.04) 0.03 
       BMI       0.01 (0.05) 0.90 
       Gender   -0.98 (0.55) 0.08 
       Education  -0.24 (0.11) 0.02 
3 Intercept   8.10 (2.52) 0.001 
       Age        -0.02 (0.04) 0.67 
       BMI       -0.05 (0.06) 0.36 
       Gender   -0.26 (0.59) 0.65 
       Education  -0.29 (0.11) 0.01 
5 Intercept   0.19 (3.34) 0.96 
       Age        0.04 (0.05) 0.42 
       BMI       -0.05 (0.06) 0.42 
       Gender   -0.07 (0.62) 0.91 
       Education  -0.10 (0.13) 0.44 
6 Intercept   -2.88 (5.00) 0.57 
       Age        -0.06 (0.06) 0.33 
       BMI        0.02 (0.06) 0.69 
 Gender   1.74 (0.73) 0.02 
 Education   0.22 (0.15) 0.14 
MCI subjects    
1 Intercept  2.70 (1.90) 0.16 
  Apoe4      1.05 (0.33) 0.002 
   Age        0.02 (0.02) 0.44 
   BMI         -0.09 (0.04) 0.02 
   Education   -0.08 (0.05) 0.14 
2 Intercept  7.76 (1.91) 0.00 
  Apoe4      1.77 (0.47) <0.001 
   Age        -0.03 (0.02) 0.26 
   BMI         -0.21 (0.05) <0.001 
   Education   -0.11 (0.07) 0.09 
3 Intercept  -1.96 (2.97) 0.51 
  Apoe4      0.40 (0.43) 0.35 
   Age        0.06 (0.03) 0.07 
   BMI         -0.01 (0.05) 0.83 
   Education   -0.14 (0.07) 0.04 
5 Intercept  -1.63 (3.52) 0.64 
 Apoe4      -0.15 (0.56) 0.79 
  Age        -0.01 (0.03) 0.75 
  BMI         -0.03 (0.07) 0.64 
   Education   0.13 (0.11) 0.22 
Note: all results  of parameter estimates were derived by using group 4 as reference 
group in both normal and MCI subjects; a SE = standard error 
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         Figure 3.1. Model based trajectories identified for baseline normal ADNI 
participants 
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Figure 3.2. Model based trajectories identified for baseline MCI ADNI participants 
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CHAPTER FOUR 
 
 
Comparison between neural network and logistic regression for dementia 
prediction: Results from the PREADViSE trial 
ABSTRACT 
                 Two reviews summarized nearly all studies about parametric predictive models 
and suggested that none are recommended for use in population dementia diagnostic 
screening. Therefore, further investigation needs to be conducted on this topic. The goal 
of this study was to apply logistic regression (parametric method) and neural network 
(non-parametric method) in a large Alzheimer’s disease prevention trial to compare the 
predictive performance of two methods. Significant covariates were entered into 
multivariate logistic regression for prediction modeling. Backward elimination was 
applied to select the final logistic regression model. Neural network was performed 
through the R package “Neuralnet” by using the same covariates as in the final logistic 
regression model. Results show that neural network had a slightly better predictive 
performance (area under curve (AUC): 0.732 in neural network vs. 0.725 in logistic 
regression). Overall, neural network has better in sensitivity (83.2%) and negative 
predicative value (98.0%) than in logistic regression’s sensitivity (72.6% ) and negative 
predictive value was (42.7% ), but not in the positive predictive value (10.0% vs. 42.8% 
). Furthermore, in logistic regression, higher education was associated with deceased 
probability of dementia. Older age, the presence of the APOE ɛ4 allele and the presence 
of a reported memory change were positively associated with having dementia. Similar 
effects were illustrated for covariate presence of APOE ɛ4 allele and memory change in 
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neural network, but not for education. Based on the result in neural network, the effect of 
education depends on age, presence of APOE ɛ4 allele and memory change. In 
conclusion, neural network performed slightly better than logistic regression in sensitivity 
and negative predictive value, and it also is able to reveal complicated relationships 
among covariates.  
INTRODUCTION 
                The rising of prevalence dementia has become a major concern for public 
health as disability associated with dementia, especially at the late stage, leads to high 
costs personally, socially and economically. Early identification of individuals with high 
risk of dementia may be of great importance to prevent or intervene dementia onset. To 
identify these high-risk individuals as earlier as possible, developing an effective 
predictive or prognostic models with risk factor is regarded as research priority. So far, 
numerous studies have been conducted to find a useful prediction model.  
                Many parametric prediction models have been predominantly developed from 
logistic regression 47-50 or proportional hazards regression analysis 51-56. For non-
parametric models, the classification tree is the most often used method 60, 61. Alternative 
approaches, also include non-parametric statistical learning methods such as random 
forest 62 and neural network analyses63. Covariates used in the majority of predictive 
modeling studies include demographic variables, such as age, education, body mass index 
(BMI), medical comorbidity (e.g., history of cardiovascular disease) or 
neuropsychological or cognitive tests. Recently, studies have incorporated genetic risk 
factors and imaging data into predictive models 53, 140.  However, studies have also argued 
that non-genetic risk factors and neuroimaging variables have not significantly increased 
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discriminative accuracy 140, and that these data are often difficult and expensive to obtain 
141. Furthermore, evidence suggests that a third of Alzheimer’s disease (AD) cases 
worldwide may be due to modifiable risk factors 142.  
                   Two systematic reviews, which summarized nearly all parametric research 
methods for prediction of dementia risk in the past decades 45, 46 , concluded that despite 
the significant increase in the number of risk modeling studies, the predictive accuracy of 
these parametric models has not changed to a significant degree (range 0.49-0.91 in 2010 
review, and 0.49-0.89 in the 2015 review) , and  none of the methods are recommended 
for dementia risk prediction in the population setting due insufficient consideration of 
sample selection, model diagnostics, and model validation 45, 46.   
                   In this study, we aim to compare the predictive performance between neural 
network and logistic regression using mainly mental status and self-reported data from 
the Prevention of Alzheimer ’s disease with Vitamin E and Selenium (PREADViSE) trial 
and also including a known AD genetic risk (APOE genotype) and clinical diagnosis of 
dementia  ) to construct a predictive model.  
METHODS  
Study sample and data sources 
                 The PREADViSE trial was an ancillary study to the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) (a large prostate cancer prevention randomized 
controlled trial (RCT))88 and was designed to evaluate the effectiveness of antioxidant 
supplements vitamin E and selenium in preventing incident AD and other forms of 
dementia. During the recruiting period from 2002 to 2009, PREADViSE enrolled 7,547 
non-demented male participants age 62 years and older (age 60 if African American) 
 51 
 
from 128 participating SELECT clinical sites in the US, Canada, and Puerto Rico. The 
eligibility criteria for participating in PREADViSE included active SELECT enrollment 
at a participating site, and absence of dementia and other active neurologic conditions 
that affect cognition such as major psychiatric disorder, including depression.  
                   The SELECT study supplements were discontinued by its Data Safety 
Monitoring Committee in 2008 following a futility analysis on its primary endpoint of 
prostate cancer incidence 89, and then participants in PREADViSE and SELECT were 
invited to continue as participants in observational cohort studies. All participants were 
invited to continue in the cohort study, and 4,271 of 7,547 original PREADViSE 
volunteers consented to participation. In order to maximize the consistency and 
completeness of follow-up, only participants who were screened in both the RCT and 
exposure phases of PREADViSE are included in the current study (N=3784). 
PREADViSE was approved by the University of Kentucky Institutional Review Board 
(IRB) as well as the IRBs at each SELECT study site. Each participant provided written 
informed consent. 
Mental status screening 
                  The Memory Impairment Screen (MIS) 91 was used as the primary screening 
instrument for memory impairment in both the RCT and observational portions of 
PREADViSE. The MIS was given annually. If participants failed the MIS (that is, the 
participant scored 5 or less out of 8 on either the immediate or delayed recall portion of 
the MIS), a second tier screen was administered. An expanded Consortium to Establish a 
Registry in AD battery (CERAD-e) 92 was used during the RCT period and the modified 
Telephone Interview for Cognitive Status (TICS-m)93 , was used during the observational 
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study. Both the CERAD-e and the TICS-m assess participants’ global cognitive function. 
Failure on the secondary screen (T score ≤ 35 on CERAD-e battery or total score ≤ 35 on 
TICS-m) would lead to a recommendation for a clinic visit with their local physician. 
Records from the clinic visit were reviewed by 3-5 expert clinicians, including two 
neurologists and at least one neuropsychologist, for a consensus diagnosis. In cases where 
the neurologists disagreed in their diagnoses, the study PI made the final determination. 
Annual screenings were completed in May 2014, and a small number of participants were 
followed for medical records through August 2015. 
Covariates 
                    APOE genotype was obtained for 3681 participants (ɛ2/2: 26 (0.71%); ɛ2/3: 
459 (12.47%); ɛ2/4: 86 (2.34%); ɛ3/3: 2240 (60.85%); ɛ3/4: 808(21.95%); ɛ4/4: 
62(1.68%)). These genotypes were converted to a dummy indicator for at least one ɛ4 
allele, where the presence of at least one ɛ4 allele was considered a carrier.  For 103 
subjects without APOE information, SAS 9.4® procedure PROC MI was used to impute 
missing values for the indicator variable based on family history of dementia. Four 
imputed data sets were generated; participants with two or more positive imputations for 
APOE ɛ4 were coded as APOE ɛ4 positive. APOE ɛ4 positivity is a major risk factor for 
AD-type dementia 96. Other data collected included age at baseline, race, BMI, years of 
education, as well as self-reported indicators of cardiovascular disease (i.e., diabetes, 
hypertension, and smoking), coronary artery bypass graft (CABG), congestive heart 
failure, hypertensive medication, and memory change at the baseline.   These data were 
obtained at enrollment and annually thereafter as recognized risk factors for dementia 97 .   
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History of significant cognitive or motor impairment due to stroke was an exclusion 
criterion, thus stroke was not considered in the models. 
Case Ascertainment 
                  To create a predictive model, we used clinical dementia status (dementia vs. 
non-dementia) at end of follow-up as the outcome. Dementia cases were identified 
through two methods during annual follow-up. First, as described above, a medical 
records-based consensus diagnosis was used. Date of diagnosis was assigned as the date 
of the failed screen. Second, because many participants were reluctant to obtain medical 
workups for their memory, additional longitudinal measures including the AD8 Dementia 
Screening Interview 94, self-reported medical history, self-reported diagnosis of dementia, 
use of memory enhancing prescription drug, and cognitive scores including the MIS, 
CERAD-e T Score, NYU Paragraph Delayed Recall, and TICS-m were used to identify 
cases. The diagnostic criteria for the second method were AD8 total of ≥ 1 (at any time 
during follow-up) to indicate functional impairment 94 plus one of the following: a self-
reported diagnosis of dementia, use of a memory enhancing prescription drug (donepezil, 
rivastigmine, galantamine, or memantine), or cognitive score below cutoffs for intact 
cognition on any test (for example: 1.5 SDs below expected performance based on age 
and education normative data95. The date of diagnosis was assigned to the earliest event.  
Data analysis    
                       Chi-square and t-test statistics were used to examine differences in 
categorical and continuous variables between dementia groups. Univariate logistic 
regressions were performed first, and only those variables significantly associated with 
probability of dementia at univariate analysis would be included in the multivariable 
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logistic regression.  Covariates included in the initial multivariable logistic regression 
model were age, education, smoking, APOE-ɛ4 allele status (any vs. none), history of 
hypertension, diabetes, coronary artery bypass graft (CABG), antihypertensive 
medication use, and memory change. In the model, age and education were used as 
continuous variables, and the rest were binary variables (yes vs. no). Logistic regression 
with backward elimination method was performed to compare with the neural network. 
Covariates age, education, APOE-ɛ4, and self-reported memory change were left in the 
final logistic regression model without interaction terms.   In the preliminary analysis, 
neural network revealed an interaction effect among years of education, age at baseline, 
status of memory change, and APOE-ɛ4 allele status. The logistic regression was then 
conducted again to confirm the interaction effects.  
Neural Network 
                      As an extension of generalized linear models (GLM), artificial neural 
network (ANN) is applied to explore the complex relationship between covariates and 
response143. Multilayer perceptron (MLP) is the main model for neural network which 
consists of vertices and directed edges called neurons and synapses in the study 
respectively. Neurons are organized as layers and connected by synapses. Our ANN 
model had three neuron layers: input, hidden, output (See figure 4.1). The input layer 
included all covariates in separate neurons, and the output layer consisted of the response 
variable (output). The layers between input and output layers are referred as hidden layers 
because they are not observed. For each synapse, a weight is attached to indicate the 
effect of the corresponding neuron. All data will pass through the neural network as 
signals, and these incoming signals will be first processed by the activation function, and 
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then by integration function to approximate output of the neuron. Based on Hornik 144, 
one hidden layer is sufficient, two or more hidden layer may be needed in some 
circumstance. An MLP with one hidden layer consisting of J hidden neurons can be 
represented by the following function: 
y  ≈  𝑔 (𝜔0 + 𝑊
𝑇 {𝑓 (𝜔0𝑗 +  ∑ 𝜔𝑖𝑗𝑥𝑖
𝑛
𝑖=1 )}𝑗=1
𝐽
 ), 
                                     = 𝑔 (𝑓 (𝜔0𝑗 +  𝑊𝑗
𝑇𝑥) ), 
where y stands for output,   𝜔0 indicates the intercept helping define the output neuron 
and 𝜔0𝑗 indicates the intercept helping define the jth hidden neuron. 𝑊𝑗
𝑇  = 
(𝜔1𝑗, … , 𝜔𝑛𝑗), which indicates the vector of weights corresponding to the synapses from 
input and leading to the jth hidden neuron, and 𝑥 = (𝑥1 , … , 𝑥𝑛) denotes the vector of all 
covariates.  
                    The function 𝑔 above denotes the integration function and is defined as  
𝑔(𝑧) = 𝑧. 
                     The function 𝑓denotes the activation function to calculate z in the above 
formula. Here, the logistic function is used: (𝑓(𝑢) =  
1
1+𝑒−𝑢 
).  
Then supervised learning is applied in which true output is defined and is compared to 
the predicted output. The starting weights are usually assigned randomly from the 
standard normal distribution143. Weights are also chosen at this stage145. To fit the neural 
network, the following steps are repeated: 
1) Neural network calculates a predicted output o(x) for given inputs x and starting 
weights. 
2) An error function E, for example, sum of squared errors (SSE)   
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𝐸 =  
1
2 
∑ ∑(𝑜𝑙ℎ − 𝑦𝑙ℎ)
2
𝐻
ℎ=1
𝐿
𝑙=1
 
or the cross-entropy  
𝐸 =  − ∑ ∑ (𝑦𝑙ℎlog (𝑜𝑙ℎ)
𝐻
ℎ=1
𝐿
𝑙=1 + (1 − 𝑦𝑙ℎ )log (1 − 𝑜𝑙ℎ)), where l = 1,…, L 
indicates  the observations, h = 1,…,H the output nodes, lh = hth nodes for lth 
observation,  
will be applied to measure the difference between the actual output and predicted 
output. 
3) Then all weights are adapted based on the rule of a learning algorithm.  
                    The process will stop if the pre-specified criterion (rule of a learning 
algorithm) is reached, for example, all components of the gradient vector of the error 
function with respect to the weights (𝜕𝐸/𝜕𝒘) are smaller in absolute value than a given 
threshold or a specified maximum step (it is referred as number of iterations) is reached. 
The resilient backpropagation algorithm (rprop+) is the most commonly used learning 
algorithm 146. Weights are modified by searching in the opposite direction of the partial 
derivatives until a local minimum is found 143. Additional technical details about ANN 
can be found in Gilnther‘s technical report and Quintana’s paper 143, 147. 
                     Our ANN input layer included four covariates including age, education, 
APOE-ɛ4, and self-reported memory change, in order to be directly comparable to the 
logistic regression model. We decided to have 10 hidden units based on the consideration 
based on literature148. The output layer had one neuron, which was dementia status at end 
of follow-up. Logistic was used as the activation function since the outcome was binary. 
Since cross entropy did not work with the data, and as indicated by Hastie in Section 
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2.3.1148, it is not unreasonable to use identity function in binary outcome, so identity 
function was applied as integration function, and sum square error was calculated. The 
“rprop+” algorithm was used to determine the weights. AUC was calculated to compare 
the performance between logistic regression and ANN on classification of dementia 
status. 
                 Descriptive analysis and logistic regression were conducted by using SAS 
9.4® (SAS Institute, Inc., Cary, NC). ANN was performed in R package “Neuralnet” 
under R (R Foundation for Statistical Computing, Vienna, Austria, version 3.1.2) 149. 
Statistical significance was set at p < 0.05.  
RESULTS 
                 Table 4.1 presents the general characteristics of participants in both RCT and 
central follow up. Of 3784 subjects, 277 had been diagnosed with dementia at the end of 
follow-up. Compared to subjects who did not develop dementia, subjects who developed 
dementia were older at baseline, less educated, were more often smokers, carried the 
APOE-ɛ4 allele, used antihypertensive medication, and reported experiencing a memory 
change at baseline (Table 4.1).  
                  Based on preliminary analysis (data not shown), the prediction error in the 
neural network did not change dramatically as the threshold of the partial derivatives of the 
error function changed; we chose 0.1 as the threshold. Figure 4.1 depicts the neural network 
structure for the current study and shows the final weights of the corresponding synapses. 
These weights were used to calculate the estimated probability of the response variable. To 
interepret the association found in the neural network, the estimated probabilities of having 
dementia for 36 hypothetical subjects are presented in Table 4.2. The measure of 
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association for having dementia given a certain covariate in the neural network depends on 
the covariate and other covariates in the model. From Table 4.2, keeping  other covariates 
in the model constant, as age increased, the estimated probability of having dementia is 
increased.  For example, for subjects 1, 2 , and 3, who represent persons who are non-
APOE- ɛ4 carriers, have no self-reported memory change, and have 17.8 years of education 
(1 standard deviation (SD) above average) and are aged at  62.2 years (1 SD below the 
average), at 67.2 years (average), and at 72.2 years (1 SD above the average), respectively, 
the estimated probabilities of developing dementia are 0.029, 0.052, and 0.068, 
respectively. Similarly, we can conclude APOE-ɛ4 allele is associated with increased 
esitmated probability of dementia.  
              As illustrated in Table 4.2, the effect of education on risk of dementia depended 
on age, APOE-ɛ4 allele status, and status of memory change. Higher education was 
associated with lower risk of dementia only in younger subjects, but not in younger 
subjects with APOE-ɛ4 and memory change. For example, in the younger age group (1 
SD below the mean age), the estimated probability (?̂? = 0.003) of having dementia for 
hypothetical subject 7 with one SD above the average for education is much lower than 
subject 1 (?̂? = 0.029) with one SD below average education. Similar comparisons can be 
made for subjects 10 (?̂? = 0.054) and 16 (?̂? = 0.002), but not for subject 28 (?̂? = 0.070) 
and subject 34 (?̂? = 0.098), who are hypothetical subjects with both APOE- ɛ4 and 
memory change. Education did not have a protective effect on risk of dementia for older 
subjects (1 SD above mean age), especially for older subjects with APOE-ɛ4 and memory 
change. No matter what education levels were, older subjects who were APOE- ɛ4 
carriers and had memory changes had the highest risk of dementia, such as subjects 30 (?̂? 
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= 0.354), 33 (?̂? = 0.364), and 36 (?̂? = 0.372) . In contrast, well-educated younger subjects 
who did not have either APOE-ɛ4 or memory changes had the lowest risk of dementia, 
such as subject 7 (?̂? = 0.003), subject 16 (?̂? = 0.002), subject 25 (?̂? = 0.001).  
                   According to the results in neural network in which the effect of education 
interacted with age, status of APOE-ɛ4, and status of memory change, logistic regression 
were performed to confirm the interaction effects. Table 4.3 shows parameter estimates 
and p values for each 3-way interaction regression model.  Education in years interacted 
with APOE-ɛ4 allele carrier, and self-reported memory changes are significantly 
associated with having dementia (p = 0.01). To demonstrate the effect modification 
identified in the logistic regression model, 36 hypothetical subjects are presented in table 
4.4. Subjects with no APOE- ɛ4 and memory change had highest estimated probability of 
having dementia, such as subject 30 (?̂? = 0.664), and subject 33 (?̂? = 0.594). Age 
modified the effect of education; however, comparing subjects 28, 29, 30, or subjects 19, 
20, 21 from table 4.4, the interaction effect among age education, APOE- ɛ4 and memory 
change is not significant. Furthermore, APOE- ɛ4 status had a stronger association with 
dementia in future than the effect of memory change when comparing subject 12 (?̂? =
0.315) to subject 21 (?̂? = 0.164), and subject 11(?̂? = 0.205) to subject 20(?̂? = 0.125), 
and so on.  
                  Comparison of overall performance between logistic regression and ANN for 
predicting incident dementia was recorded in Table 4.5. ANN had slightly better 
predictive accuracy than logistic regression (AUC in neural network = 0.732 vs. AUC in 
logistic regression 0.725). Overall, neural network has better in sensitivity (83.2%) and 
negative predictive value (98.0%) than sensitivity (73.6%) and negative predictive value 
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(97.2%) in logistic regression, but worse in the positive predictive value (10.0% in neural 
network vs. 41.4% in logistic regression).  
DISCUSSION  
             The purpose of this study was to compare predictive accuracy for incident 
dementia between neural network and logistic regression in the PREADViSE trial. 
Neural network showed slightly improved predictive accuracy (AUC = 0.732) compared 
in logistic regression (AUC = 0.725). The model obtained from the neural network had 
slightly better sensitivity and negative predict value, but worse in positive predictive 
value. Similar association between covariates and the outcome were found in neural 
network and logistic regression, but the model in neural network is more difficult to 
interpret than logistic regression. Furthermore, neural network can easily identify more 
complex relationships among model variables, here education and age, APOE, and self-
reported memory change. While higher education is usually considered universally 
protective against dementia 150, 151, the effect of education on dementia in the neural 
network depended on age, APOE-ɛ4 allele status, and self-reported memory change.  
                    Stephan et al45 evaluated predictive accuracy of dementia prediction models 
and found that poor predictive accuracy is associated with single-factor models, long 
follow-up intervals, and all-cause dementia for outcome ascertainment, which assumes all 
dementias share risk factors. The Canadian Study of Health and Aging (CSHA) 152 
showed lower predictive accuracy (AUC = 0.77 in 10-year follow-up than 5 –year follow 
up (AUC = 0.83).  The predictive accuracy (AUC = 0.732) in our neural network model 
is slightly lower than the CSHA 10-year study, but is comparable to the Gothenburg H-70 
1902-02 birth cohort for 10-years of follow-up (AUC = 0.74)153. In contrast to the CSHA 
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study, Exalto et al did not find any significantly different results on predictive accuracy in 
two Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) studies 
based on follow-up time (one is 10 years follow-up and another one is 36 years )59, 154. 
Follow-up time in the current study was over 10 years. 
                   Based on covariates used to generate the predictive model, models generated 
in the previous papers can be summarized into the following categories: 1) demographic 
only model; (2) cognitive tests based models with or without demographic data; (3) 
comorbidity data model; (4) genetic and biomarker model; (5) models including 
demographics, comorbidities, genetics, and biomarkers. Our logistic regression model 
included age, education, APOE, and memory changes to predict incident dementia and 
had moderate predictive accuracy (AUC: 0.725, sensitivity 73.6% and specificity 60.7%). 
Another similar study 154in which the model was derived from demographic variables, 
health risk factors and APOE, obtained slightly better diagnostic accuracy (AUC = 
0.78).This study also argued that diagnostic accuracy will not change significantly after 
removing APOE from the model (AUC: 0.77; sensitivity 77% and specificity 63%). 
Other models include neuroimaging information and/or neuropsychological tests. Tang et 
al. argued in their review that genetic information and/or imaging data do not improve 
diagnostic accuracy significantly 46, 140. Furthermore, predictive models using one or 
multiple neuropsychological tests as covariates seem to have higher predictive accuracy, 
but there is not direct comparison for these two approaches due to between-study 
variation, such as different criteria on outcome measurement45. Waite and colleagues 
argued that refining the subgroups of dementia types may improve diagnostic accuracy, 
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but is unlikely to be cost effective because defining these subgroup of dementia can be 
expensive155.  
                        On the other hand, from machine learning and classical statistical 
methods, neural network in several studies has demonstrated superior ability to identify 
complex relationships in data compared to classical statistical methods156, 157. Also, neural 
networks obtained higher predictive accuracy rate than linear discriminant analysis and 
successfully distinguished Alzheimer’s patients from control aged 80 years and older in 
the Nun study using neurofibrillary tangles and neurotic plagues counts (AUC was not 
reported) 158. In contrast, Maroco et al.159 suggested that random forest and linear 
discriminant analysis performed better than other statistical methods, such as neural 
network, support vector machines, and logistic regression based on the consideration of 
predictive accuracy, sensitivity, specificity. They also argued that neural networks and 
logistic regression are inappropriate for unbalanced data, which means small frequency 
vs. large frequency group in response variable160-163. 
Furthermore, Song et al. 164 compared the machine learning methods with classic 
statistical methods for two biomedical datasets: one was from patient care records and 
another was from a population survey, and they did not find significant differences in 
prediction between the two datasets, which indicates that the quality of the questionnaire 
may be more important than accuracy of the answers in the questionnaire.  
                Strengths for this study include larger sample size and long follow-up. We were 
also able to consider most well-established risk factors for dementia, including 
demographic, genetic, and medical characteristics, including cardiovascular risk factors.  
This study also had some limitations. Our outcome diagnosis was based on two criteria 
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due to lack of medical records from many participants, our case ascertainment may be 
less accurate.  However, misclassification of diagnosis is independent of exposure 
measurement, so no differential misclassification is unlikely. Thus, results are likely 
biased toward the null.    
                 In conclusion, neural network did not significantly improve predict accuracy 
over logistic regression and also increased difficulty of interpretation of the association 
between the outcome and covariates. The most important to improve performance of a 
model, does not depend on statistical methods, or computational techniques, but depends 
on how much accurate information the dataset contain. In future, the similar study should 
focus on refining the definition of outcome diagnosis, improving quality of questionnaire, 
performing validation after generating a risk model.   
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Table 4.1. General Characteristics of participants in PREADViSE 
 
Characteristic 
All Subjects 
(N=3784) 
No Dementia 
(n=3557) 
Dementia 
(n=227) 
 
P value  
Baseline ageb, y 67.2±5.0 67.0±5.0 70.1±5.2 < 0.001 
Educationb, y  15.5±2.3 15.5±2.3 15.0±2.5 0.002 
Black racec 318 (8.4) 294 (8.3) 24 (10.6) 0.22 
Baseline smokingc 2018 (53.4) 871(52.9) 85 (61.2) 0.01 
APOE-ɛ4 (≥1 ɛ4)c 956 (25.3) 1876 (24.5) 153 (37.4) < 0.001 
Baseline hypertensionc 2998 (39.7) 2703 (38.6) 295 (53.4) <0.001 
Baseline diabetesc 354 (9.4) 322 (9.1) 32 (14.1) 0.01 
Baseline BMIab, kg/m2 28.4±4.3 28.4±4.3 28.4±4.5 0.93 
Baseline CABGac 135 (3.6) 119(3.4) 16(7.1) 0.004 
Baseline Congested Heart diseasec 18(0.5) 16(0.5) 2(0.9) 0.36 
Baseline antihypertensive 
medicationc 
1413 (37.3) 1308(36.8) 105(46.3) 0.004 
Memory changec 852 (22.5) 762 (21.4) 90 (39.7) <0.001 
aBMI: Body Mass Index; CABG: Coronary artery bypass graft;b mean ± standard deviation; ccount (%). 
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Table 4.2. Illustration effect of education by age, APOE-ɛ4 allele and memory change 
status for hypothetical subjects from neural network 
 
 Agea 
 Old  Average  Young 
Educationb Subject 
ID 
?̂?c 
 Subject 
ID 
?̂?c 
 Subjects 
ID 
?̂?c 
Absence of APOE- ɛ4 allele  and  Absence Memory change   
Low 3  0.068  2 0.053  1 0.029 
      Average 6  0.066  5 0.046  4 0.018 
High 9  0.062  8 0.037  7 0.003 
Presence of APOE- ɛ4 allele   and Absence of memory change 
Low 12 0.148  11 0.103  10 0.054 
     Average 15 0.128  14 0.079  13 0.028 
High 18 0.104  17 0.053  16 0.002 
Absence of APOE- ɛ4 allele  and  Presence of memory change   
Low 21 0.145  20 0.126  19 0.091 
      Average 24 0.113  23 0.096  22 0.048 
High 27 0.100  26 0.053  25 0.001 
Presence of APOE- ɛ4 allele  and  Presence of memory change   
Low 30 0.354  29 0.056  28 0.070 
      Average 33 0.364  32 0.071  31 0.084 
High 36 0.372  35 0.058  34 0.098 
Note: Note : aYoung = 62.2 years , Average = 67.2 years, Old = 72.2 year ; bLow =13.2 years of education, 
Average =15.5 years of education, High = 17.8 years of education; c?̂? = estimated probability of having 
dementia 
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Table 4.3 Parameter estimates from interaction of logistic regression 
Variables Estimate (SE) P value 
Intercept 4.78(5.59) 0.39 
Age at baseline -0.10(0.08) 0.22 
Education in years -0.91(0.37) 0.01 
Presence of  APOE- ɛ4 allele -1.91(2.11) 0.37 
Presence of memory change 2.45(2.07) 0.24 
Age at baseline  * Presence of  APOE- ɛ4 allele 0.05(0.03) 0.04 
Age at baseline  * education in years 0.01(0.005) 0.02 
Age at baseline  * Presence of  memory change -0.002(0.03) 0.91 
Education in years  * Presence of  APOE- ɛ4 allele -0.08(0.07) 0.30 
Presence of  APOE- ɛ4 allele * Presence of  memory change -4.85(1.99) 0.01 
Education in years * Presence of  memory change -0.10(0.07) 0.18 
Education in years *Presence of  APOE- ɛ4 allele * Presence of  memory change 0.32(0.13) 0.01 
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Table 4.4.  Estimated probability of having dementia from multivariable logistic 
regression to illustrate interaction effects among age at baseline, education,  APOE- ɛ4 
allele and memory change 
 
 Agea 
 Old  Average  Young 
Educationb Subject 
ID 
?̂?c 
 Subject 
ID 
?̂?c 
 Subjects 
ID 
?̂?c 
Absence of APOE- ɛ4 allele  and  Absence Memory change   
Low 3  0.059  2 0.044  1 0.032 
      Average 6  0.055  5 0.036  4 0.023 
High 9  0.051  8 0.029  7 0.016 
Presence of APOE- ɛ4 allele   and Absence of memory change 
Low 12 0.315  11 0.205  10 0.126 
     Average 15 0.299  14 0.172  13 0.091 
High 18 0.284  17 0.143  16 0.066 
Absence of APOE- ɛ4 allele  and  Presence of memory change   
Low 21 0.164  20 0.125  19 0.095 
      Average 24 0.126  23 0.084  22 0.055 
High 27 0.097  26 0.056  25 0.032 
Presence of APOE- ɛ4 allele  and  Presence of memory change   
Low 30 0.664  29 0.525  28 0.382 
      Average 33 0.594  32 0.415  31 0.256 
High 36 0.519  35 0.313  34 0.161 
Note: Note : aYoung = 62.2 years , Average = 67.2 years, Old = 72.2 year ; bLow =13.2 years of education, 
Average =15.5 years of education, High = 17.8 years of education; c?̂? = estimated probability of having 
dementia 
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Table 4.5. Comparison of predictive performance of logistic regression and 
neural network 
 Logistic regressiona Neural networka 
Sensitivity 73.6% 83.2% 
Specificity 60.7% 51.4% 
Positive Predictive Value 41.4% 10.0% 
Negative Predictive Value 97.2% 98.0% 
Note : aArea under curve : 0.725 in logistic regression and 0.732 in neural network 
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Figure 4.1 . Graphics of neural network  for incidence of dementia in PREADViSE trial. Age, APOE-ɛ4, Education, Memory 
Change represent the 4 input neurons on the left side of the diagram. Each input neuron was connected with 10 hidden neurons (second 
column of empty circles from the left of figure) by 10 corresponding synaptic weights. The 10 hidden units and the output neuron – 
dementia were connected by the synapses starting the hidden units and ending at the output layer. The first “1” in the circle from the left of 
the figure represents the intercepts of each hidden neuron, and the second “1” in the circle stands for the intercept of output neuron. These 
weights and intercepts were adapted to calculate the estimated probability of dementia. The model was stopped after 203313 steps, and 
predication error is 99.02907. 
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CHAPTER FIVE 
 
Conclusion 
Summary 
 
               Understanding its prevalence, risk factors, and development and potential 
interventions for dementia is becoming an important facet of public health and health 
care delivery. The purpose of this dissertation was to develop further the body of 
literature about risk factors, development, and prediction of dementia. Two datasets 
including Prevention of Alzheimer’s Disease with Vitamin E and Selenium 
(PREADViSE trial) and Alzheimer’s Disease Neuroimaging Initiative(ADNI) were used 
to conduct three studies: (1) “Self-reported sleep apnea and dementia risk: Findings from 
the PREADViSE Alzheimer’s disease prevention trial;” (2) “Evaluating  trajectories of 
episodic memory in normal cognition and mild cognitive impairment: results from 
ADNI;” (3) “Comparison between neural network and logistic regression in 
PREADViSE trial.”  The major findings from these studies are summarized below:  
          
                    Chapter Two examined the association between self-reported sleep apnea at 
baseline and risk of dementia in a U.S. male population. This was the first study to 
investigate this topic in this population using a cohort study. Two cohort studies82, 83 had 
shown that sleep apnea is significantly associated with risk of dementia in U.S. female 
and Taiwanese population. By contrast, a few cross-sectional studies found no 
association between sleep apnea and cognitive decline. One the other hand, one small 
cross-section study and one ADNI study suggest that the association between sleep apnea 
and dementia depends on the status of APOE-ɛ4.  We demonstrated that sleep apnea in 
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general is not associated with risk of dementia in U S male population. However, for 
APOE-ɛ4 non-carrier, men with sleep apnea had an estimated 66% increased risk to 
develop dementia.  
                 Considering longitudinal studies feature of dementia studies, Chapter Three 
shifts focus to the trajectory of development into dementia. Many statistical methods 
including linear mixed effect model, Markov processes, multi-stage disease progression 
model, have been applied to investigate change or trajectory of cognitive and 
neuropsychological measurement over time. Nagin and colleagues developed the group 
based trajectory model (GBTM) which accommodates the discrete nature and truncated 
distribution of outcome. It assumes that the sample is composed of a mixture of distinct 
groups, and that each group of individuals follows a similar developmental trajectory in 
terms of changes at mean level of outcome measurements 38-41.  Furthermore, one 
advantage of GBTM is that it qualitatively identifies distinct developmental groups that 
may not be identifiable by using LMM 42, 43. Another advantage is that the model can 
distinguish real differences from chance variation. Chapter Three explored potential 
trajectories in episodic memory scores in normal and MCI subjects enrolled in the ADNI 
and assessed whether the risk factors that influence these trajectories differ by cognitive 
status using GBTM. 
              This study confirmed heterogeneity of episodic memory in both baseline normal 
and MCI subjects. In baseline normal subjects, 6 distinct trajectories were identified 
based on the baseline value of  RAVLT 30 min-delayed recall and shape of trajectory 
during years  while 5 trajectories in MCI subjects. Accounting baseline scores, the 6 
group trajectories in baseline cognitive normal subjects can be summarized as three type 
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of trajectories: stable (Group 3 and Group 6), linear decline (Group 1 and Group 2), and 
curvilinear decline (Group 4 and Group 5). About a third of baseline normal subjects will 
remain cognitively normal over time, and about 28% of subject’s present curvilinear 
decline.  In contrast to the trajectories identified for normal subjects, all 5 trajectories 
group for MCI showed the tendency to decline. Over 65% subjects remained MCI 
throughout follow-up. Subjects with trajectories in Groups 1 and 2 were more likely to 
progress to dementia.  The study also confirmed that disparate outcomes for MCI 
subjects.  About 11% and 22% MCI subjects in Groups 4 and 5, respectively, were 
reverted back to normal cognitive states and 19% and 13% were converted to dementia, 
respectively.  Furthermore, the study demonstrate different demographic variables were 
significantly associated with different trajectories in normal and MCI subjects. Age, 
education, BMI are significantly associated with trajectories for normal and MCI 
subjects. However, APOE is only significantly associated with trajectories for MCI 
subjects. 
              In Chapter Four, we aimed to compare predictive performance from parametric 
and non-parametric method using PREADViSE study. Two recently systematic reviews 
reported nearly all parametric research methods for prediction of dementia risk in the past 
decades 45, 46 and recommend that none of them are recommended for dementia risk 
prediction in the population setting due to sample selection, model diagnostics, and 
model validation 45, 46. Several non-parametric methods were commonly used including 
classification tree, random forest, and neural network. Chapter 4 compared the 
performance of logistic regression and neural network and found that neural network 
obtains slightly improved predictive accuracy (AUC = 0.732) comparing to predictive 
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accuracy (AUC = 0.725) in logistic regression. Neural network obtain similar association 
between covariates and outcomes as logistic regression did. Moreover, neural network 
can demonstrate more complex relationships among covariates. Based on finding from 
neural network, the effect of years of education on risk of dementia depends on APOE-ɛ4 
allele, years of age, self-reported memory change.  
 
Strengths and limitations 
 
               A major strength of this dissertation is that two datasets used in this dissertation 
were drawn from two large and clinically well-defined longitudinal study with adequate 
follow-up time (over 11 years in PREADViSE and 9 years in ADNI study). Long –time 
follow-up can lead to more incident cases to increase power of survival analysis and 
provide adequate data points to investigate the development of dementia. Furthermore, 
the dissertation will enrich the body of literature about dementia from comprehensive 
aspects including prevention (finding risk factor of dementia, chapter 2), development 
(trajectory of episodic memory, chapter 3), and prediction (predictive of model of 
dementia, chapter 4) of dementia.  
                    In chapter 2, survival analysis was conducted for the first time in U.S. male 
population for association between self-reported sleep apnea and risk of dementia. The 
limitation for this chapter may include missing cases or misclassification of exposure or 
outcome. However, use of the AD8 functional status screen demonstrated better 
agreement with medically-confirmed ascertainment, which improve ascertainment of 
cases.  Based on the phrasing of questionnaire for self-reported measure of sleep apnea, it 
is most likely that non-differential misclassification happened, which should only lead to 
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the results towards null.   In chapter three, we applied group trajectory based model to 
illustrate episodic memory trajectory in baseline cognitive normal and MCI subjects, 
which is semi-parametric model developed by Nagin. The model assumes that the sample 
is composed of a mixture of distinct groups, and that each group of individuals follows a 
similar developmental trajectory in terms of changes at mean level of outcome 
measurements 38-41. And there are only a few paper available in the literature on how to 
apply and fit GBTM, which could be a better statistical methods for longitudinal 
dementia studies.  However, GBTM has its limitation, which is that the direct relationship 
between outcome (dementia) and risk factors (such as age education, gender, etc) does 
not exist, so we cannot quantitatively interpret the association between outcomes and 
covariates as routine. We applied neural network, a novel statistical learning method and 
compared it to the logistic regression in chapter 4. The better strategy to compare neural 
network and logistic regression is to perform validation, then compare the predictive 
performance between neural network and logistic regression.  
   
Future Research  
                 Several avenues of future research have been suggested by the studies in the 
dissertation. First, replication study using objective measure of sleep apnea and consistent 
diagnosis of incident dementia for chapter 2 are needed to confirm the association 
between sleep apnea and risk of dementia. As discussed above, rigorous outcome 
diagnosis criteria are called to improve ascertainments of incident cases. Furthermore, 
measurement of sleep apnea in chapter 2 came from self-reported questionnaire which 
may cause non differential misclassification. Objective measure of sleep apnea such as 
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apnea-hypopnea index, are needed to recheck the association. Many sleep apnea subjects 
who were taking sleep treatments, such as Continuous Positive Airway Pressure (CPAP) 
therapy or pills. In future study, we also wonder whether or how much these treatments 
influence the association between sleep apnea and risk of dementia.  
                In Chapter Three, we examined the trajectory of RAVLT 30-mimtute delayed 
recall as index of episodic memory in normal and MCI subjects. In the future, we would 
assess trajectory of other test scores of RAVLT, which represent different aspects of 
cognitions.  In additional to RAVLT, we also propose to investigate a series of 
trajectories of other neuropsychological tests, such as dysexecutive components using 
data in ADNI. Moreover, we are also interested in finding the best index whose trajectory 
is the most associated with conversion or progression to dementia.  MCI in ADNI 1 were 
generally defined and it was not determined the specific stage or time of MCI. In 
ADNGO, and ADNI2, two specific group MCI subjects: early MCI and later MCI were 
recruited, it will be interesting to study the specific trajectories for these subpopulation.  
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Appendix   
Table 1s:   Mean and Standard deviation of 30 min delayed recall of RAVLT baseline at each follow-up assessment 
 
 
 
Month 
Normal 
  
MCI 
 Overall 
(n) 
Group 1 
(n ) 
Group 2 
(n ) 
Group 3 
(n ) 
Group 4 
(n) 
Group 5 
(n ) 
Group 6 
(n ) 
 Overall 
(N ) 
Group 1 
(n) 
Group 2 
(n ) 
Group 3 
(n ) 
Group 4 
(n) 
Group 5 
(n) 
RAVLT 0 7.4±3.7(217) 3.3±1.8(33) 6.2±2.7(58) 6.9±3.0(42) 9.4±3.1(31) 9.1±2.2(30) 12.9±2.3(22)  2.9 ±3.3(371) 1.5±1.6(143) 0±0(66) 3.3±1.9(66) 5.6±3.0(73) 10.1±3.2(23) 
 6 6.9±3.5(215) 2.5±1.8(30) 4.7±2.0(58) 7.4±2.1(44) 9.4±2.2(31) 8.5±2.1(30) 11.9±2.8(22)  2.3±3.1(367) 0.8±0.9(143) 0±0(65) 2.6±1.9(64) 4.6±2.7(72) 10.0±2.7(23) 
 12 7.9±3.7(208) 3.5±2.2(30) 6.0±2.3(52) 7.6±2.7(44) 10.5±2.2(31) 9.2±2.2(30) 13.6±1.4(21)  2.4±3.5(347) 0.5±0.8(138) 0±0(57) 2.7±1.8(62) 5.2±3.0(67) 11.4±2.3(23) 
 18a - - - - - - -  2.1±3.1(315) 0.4±0.7(122) 0±0(52) 1.8±1.7(57) 5.2±2.7(64) 9.2±2.7(20) 
 24 8.1±4.0(199) 2.8±2.6(29) 6.1±2.2(51) 7.8±2.3(40) 11.7±1.6(30) 9.8±2.5(29) 13.4±3.0(20)  2.3±3.5(289) 0.3±0.7(114) 0±0(44) 2.3±1.9(55) 5.1±3.0(55) 11.0±2.8(21) 
 36 6.8±3.7 (183) 1.4±1.7(24) 4.2±1.9(45) 7.6±1.6(38) 10.0±1.9(28) 7.8±1.6(29) 12.3±2.4(19)  2.2±3.4(243) 0.2±0.5(86) 0.2±0.4(
32) 
1.5±1.5(52) 4.3±2.4(53) 10.5±3.5(20) 
 48 7.5±4.3(120) 2.0±1.9(15) 4.3±2.6(28) 7.8±2.9(29) 11.4±1.6(18) 7.7±2.1(18) 14.4±1.0(12)  2.1±3.3(141) 0.1±0.4(46) 0.1±0.4(
20) 
1.7±1.7(34) 4.7±2.9(30) 8.6±4.3(11) 
 60 6.9±4.4(106) 1.6±1.6(13) 3.8±2.6(23) 7.0±2.4(27) 10.1±2.9(19) 6.6±3.6(13) 14.1±1.4(11)  2.4±3.8(106) 0.1±0.2(31) 0±0(12) 1.0±1.5(28) 4.7±2.8(25) 11.2±3.6(10) 
 72 7.1±4.5(110) 1.0±1.4(12) 4.2±2.1(24) 7.8±2.5(25) 10.8±2.0(19) 4.9±3.1(18) 14.6±0.9(12)  2.7±4.1(101) 0.1±0.3(27) 0.1±0.3(
11) 
1.2±1.3(24) 4.2±3.6(27) 11.2±3.6(12) 
 84 7.4±4.5(95) 1.4±1.9(9) 3.4±2.5(17) 7.7±2.2(23) 10.5±2.4(18) 5.1±3.1(15) 14.2±1.0(13)  2.6±3.8(75) 0±0(17) 0±0(6) 1.3±1.3(20) 3.5±2.7(21) 8.8±5.3(11) 
 96 5.8±4.7(63) 0.4±0.9(5) 3.1±1.7(14) 7.9±2.1(15) 9.6±2.9(10) 1.5±2.2(13) 14.3±0.8(6)  2.2±3.2(54) 0.1±0.3(11) 0±0(4) 0.8±1.4(11) 3.7±2.9(21) 5.0±5.1(7) 
 108b 5.8±5.1(13) 6.0±0(1) 4.5±2.1(2) 10.3±2.9(3) 7.0±2.8(2) 0±0(4) 15±0(1)  4.1±5.3(10) 0±0(3) - - 5.2±3.8(5) 7.5±10.6(2) 
Note:  a Baseline normal subjects were not assessed in 18 months; bNone of  MCI subjects in  group 1 and group2  were assessed at 108 month  
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Figure 1s. Model based trajectories overlaid with crude trajectories for normal ADNI subjects. Solid lines indicate model based 
trajectories and dash lines stand for crude trajectories. The model based trajectories show discrepancy with crude trajectories at 
the end points of follow up.   
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Figure 2s. Model based trajectories overlaid with crude trajectories for MCI ADNI subjects. Solid lines indicate model based 
trajectories and dash lines stand for crude trajectories. The model based and crude trajectories demonstrate good match for 
Group1-4, but not in Group 5, which may be due to less participants in that group and/or mean- variance relationship (larger 
mean goes with large variance) in ZIP distribution.  
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